Fact-checked by Grok 2 weeks ago

Autoimmune disease

Autoimmune diseases are a diverse group of over 100 disorders in which a person's immune system mistakenly attacks the body's own healthy cells, tissues, and organs, leading to inflammation, damage, and impaired function.^[1] These conditions can affect nearly any part of the body, from joints and skin to vital organs like the heart, lungs, and endocrine glands, and they range from mild, localized issues to severe, life-threatening illnesses that often require lifelong management.^[2] Autoimmune diseases collectively impact estimates of 4-8% of the U.S. population (around 15-25 million people as of 2025), making them a significant public health concern, and they disproportionately affect women, comprising about 80% of cases due to factors such as genetics, hormones, and environmental influences.^[1]^[3] Common examples include rheumatoid arthritis, which causes joint inflammation and deformity; systemic lupus erythematosus (SLE), a multisystem disorder affecting skin, kidneys, and other organs; multiple sclerosis, involving damage to the central nervous system; type 1 diabetes, where the immune system destroys insulin-producing cells in the pancreas; and psoriasis, characterized by scaly skin plaques.^[4] These diseases often cluster in families, suggesting a genetic component, and their prevalence has been increasing by 3-12% annually, possibly due to improved diagnostics and environmental changes.^[5]^[6] The precise causes of autoimmune diseases remain incompletely understood but generally arise from a breakdown in immune tolerance, where genetic susceptibility interacts with environmental triggers such as viral or bacterial infections, exposure to chemicals like pesticides or mercury, cigarette smoking, and even sunlight or dietary factors like vitamin D deficiency.^[2]^[4] Diagnosis is challenging and typically involves a combination of medical history, physical exams, blood tests for autoantibodies, imaging, and sometimes biopsies, as no single test confirms the presence of an autoimmune disorder.^[2] Treatments focus on reducing immune activity, alleviating symptoms, and preventing complications, often using corticosteroids, immunosuppressant drugs, biologics, and lifestyle modifications, though no cures exist and many patients experience flares and remissions throughout life.^[1] Ongoing research emphasizes early intervention, personalized therapies, and exploring preventive strategies to address the rising burden of these chronic conditions.^[1]

Overview

Definition

Autoimmune diseases are a group of disorders in which the immune system erroneously targets and damages the body's own healthy cells, tissues, and organs, resulting in chronic inflammation and potential tissue destruction.^[7] This malfunction arises from a failure in immune tolerance, where self-reactive lymphocytes evade normal regulatory mechanisms and initiate pathological responses against self-antigens.^[1] The resulting damage can vary in severity and may lead to a wide array of clinical manifestations, though the underlying process consistently involves aberrant adaptive immunity.^[4] The concept of autoimmunity was first articulated in the early 20th century by Paul Ehrlich, who introduced the term "horror autotoxicus" in 1904 to describe the immune system's inherent prohibition against attacking its own constituents, viewing such self-reactivity as a forbidden phenomenon.^[8] Although Ehrlich's framework highlighted the theoretical possibility, experimental evidence of autoantibodies emerged later, with the first discoveries in the 1940s, including antinuclear antibodies and rheumatoid factors, marking the recognition of autoimmunity as a disease mechanism.^[9] Autoimmune diseases are distinct from other immune disorders, such as immunodeficiencies, which stem from inadequate or absent immune responses leading to increased infection susceptibility, and allergies, which involve hyperactive reactions to external, non-self allergens like pollen or food proteins.^[10] In contrast, autoimmunity represents a dysregulated hyperactivity directed inward, breaching self-tolerance without external provocation.^[11] These conditions collectively affect an estimated 8–10% of the global population as of 2023–2025, encompassing more than 80 distinct diseases that impose significant morbidity worldwide. Recent studies indicate an increasing trend in prevalence, possibly due to improved diagnostics and environmental factors.^[12]^[1]

Classification

Autoimmune diseases are broadly classified into systemic, organ-specific, and mixed categories based on the extent and localization of immune-mediated damage. Systemic autoimmune diseases involve widespread inflammation affecting multiple organs and tissues, often through autoantibodies targeting ubiquitous antigens such as DNA-protein complexes found in various cell types.^[13] Examples include systemic lupus erythematosus (SLE), which impacts the skin, joints, kidneys, and other organs; rheumatoid arthritis, primarily affecting joints but with systemic manifestations; and scleroderma, involving skin and internal organs like the lungs and gastrointestinal tract.^[14] These conditions are frequently managed under the umbrella of rheumatic autoimmune diseases.^[13] In contrast, organ-specific autoimmune diseases target a single organ or tissue, with the immune response directed against localized self-antigens.^[13] Representative examples are Graves' disease, where autoantibodies stimulate the thyroid gland leading to hyperthyroidism; type 1 diabetes mellitus, characterized by T-cell destruction of pancreatic beta cells; and multiple sclerosis, involving immune attack on myelin in the central nervous system.^[15] This category highlights the immune system's aberrant focus on tissue-restricted antigens, often resulting in localized pathology.^[16] Mixed or overlap autoimmune diseases exhibit features of multiple categories, blending systemic and organ-specific elements without fully meeting criteria for a single defined condition.^[17] For instance, mixed connective tissue disease (MCTD) combines symptoms of SLE, scleroderma, and polymyositis, driven by high-titer anti-U1 RNP antibodies.^[18] Undifferentiated connective tissue disease (UCTD) represents an overlap syndrome where patients display clinical and serological signs of autoimmunity—such as positive antinuclear antibodies—but do not satisfy diagnostic thresholds for established connective tissue diseases like SLE or rheumatoid arthritis, often persisting in this ambiguous state or evolving over time.^[17] These overlap cases underscore the heterogeneity of autoimmunity and the challenges in precise categorization.^[19] Classification extends beyond anatomical involvement to include immunological criteria, such as the predominant immune pathway and target antigens. Diseases may be distinguished as antibody-mediated, involving B-cell production of autoantibodies against extracellular or cell-surface antigens (e.g., SLE with anti-dsDNA antibodies), or cell-mediated, featuring T-cell responses against intracellular antigens (e.g., type 1 diabetes targeting islet cells).^[15] Target antigens further refine groupings, with systemic diseases often involving nuclear or cytoplasmic components, while organ-specific ones focus on tissue-unique proteins.^[16] Clinical patterns, including serological profiles and disease progression, also inform classification, aiding in diagnosis and management.^[13] Approximately 80 to 100 autoimmune diseases are currently recognized, though estimates range up to 150 due to ongoing identification of rare variants; these are often grouped into more than 20 categories for research and clinical purposes, reflecting shared mechanisms and antigens.^[1] This framework provides a taxonomy for understanding the diversity of autoimmune disorders while accommodating overlaps and evolving definitions.^[16]

Pathophysiology

Normal Immune Tolerance

Central tolerance is the primary mechanism by which the immune system eliminates self-reactive lymphocytes during their development in primary lymphoid organs, thereby preventing autoimmunity. In the thymus, immature T cells, or thymocytes, undergo negative selection where those with T cell receptors (TCRs) that bind strongly to self-antigens presented by major histocompatibility complex (MHC) molecules on thymic antigen-presenting cells are induced to undergo apoptosis or become anergic. This process occurs mainly in the thymic medulla, involving medullary thymic epithelial cells (mTECs) that express a diverse array of tissue-restricted self-antigens. Similarly, in the bone marrow, developing B cells expressing B cell receptors (BCRs) that recognize self-antigens with high affinity are deleted through apoptosis or edited to alter their specificity, ensuring central B cell tolerance.^[20] A critical regulator of central T cell tolerance is the autoimmune regulator (AIRE) gene, which drives the ectopic expression of thousands of peripheral tissue-specific antigens in mTECs, facilitating their presentation to thymocytes for negative selection. Mutations in AIRE, first identified through positional cloning in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), disrupt this process, leading to impaired self-antigen presentation and systemic autoimmunity. Complementing deletion, some self-reactive thymocytes may be diverted into the regulatory T cell (Treg) lineage, providing an additional layer of central tolerance. In the bone marrow, central tolerance for B cells also includes receptor editing, where light chain genes are rearranged to reduce self-reactivity, though negative selection remains dominant for high-affinity autoreactive clones.^[21]^[20] Peripheral tolerance mechanisms operate outside the thymus and bone marrow to suppress or eliminate any self-reactive lymphocytes that escape central tolerance, maintaining immune homeostasis in secondary lymphoid organs and tissues. Key processes include the action of regulatory T cells (Tregs), which are CD4+ Foxp3+ lymphocytes that actively suppress autoreactive T cell responses through cytokine secretion (e.g., IL-10, TGF-β) and cell-contact inhibition. The transcription factor FOXP3 is indispensable for Treg development and suppressive function; its ectopic expression in conventional T cells confers regulatory activity, while its deficiency causes severe autoimmunity, as seen in immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome. Anergy represents another peripheral mechanism, wherein T cells receiving TCR signals without sufficient costimulation (e.g., CD28-B7 interaction) enter a hyporesponsive state, preventing proliferation and effector function. Additionally, apoptosis, or peripheral deletion, eliminates activated autoreactive T cells via Fas-FasL interactions or Bim-mediated intrinsic pathways, often triggered by chronic self-antigen exposure.^[22]^[23] These tolerance mechanisms collectively establish a delicate balance, suppressing autoimmunity by curtailing responses to self-antigens while permitting robust immunity against pathogens. Tregs, in particular, fine-tune this equilibrium by limiting excessive inflammation during infections without compromising pathogen clearance, as their transient depletion enhances antimicrobial responses but risks tissue damage if prolonged. This dynamic regulation ensures that the immune system distinguishes self from non-self, with failures in tolerance tipping toward autoimmunity and over-suppression favoring chronic infections.^[24]^[23]

Mechanisms of Autoimmunity

Autoimmunity arises from the pathological failure of immune tolerance mechanisms, allowing self-reactive lymphocytes to persist and initiate immune responses against the body's own tissues. This breakdown involves defects in both central and peripheral tolerance, leading to the activation of autoreactive B and T cells, production of autoantibodies, and subsequent inflammatory cascades that perpetuate tissue damage.^[25]^[26] Central tolerance fails primarily in the thymus and bone marrow, where negative selection eliminates autoreactive T and B cells during development. Defects in this process, such as impaired expression of the autoimmune regulator (AIRE) gene, prevent the proper presentation of self-antigens, allowing autoreactive clones to escape into the periphery. For instance, mutations in AIRE underlie autoimmune polyendocrine syndrome type 1, where thymic defects lead to multiorgan autoimmunity.^[25]^[26] Peripheral tolerance mechanisms, which maintain control over escaped self-reactive cells in the periphery, also falter, often due to dysfunction in regulatory T cells (Tregs). Tregs, dependent on transcription factors like FOXP3, suppress autoreactive responses through mechanisms including cytokine modulation and direct cell contact; their impairment, as seen in IPEX syndrome from FOXP3 mutations, results in uncontrolled T-cell activation and widespread autoimmunity. Additionally, failures in peripheral anergy—where self-reactive T cells become unresponsive—contribute to the persistence of these cells.^[25]^[26] B-cell hyperactivity drives autoantibody production, with autoreactive B cells evading checkpoints like receptor editing and clonal deletion in the bone marrow. This leads to the generation of high-affinity IgG autoantibodies against self-antigens, such as anti-double-stranded DNA antibodies in systemic lupus erythematosus (SLE), facilitated by somatic hypermutation in germinal centers. In SLE, defects in early B-cell checkpoints allow mature naive B cells to produce autoantibodies even prior to antigen encounter, amplifying the autoimmune response.^[25]^[26] T-cell mediated damage involves both CD4+ and CD8+ T cells, which infiltrate self-tissues and directly attack via cytotoxic mechanisms and cytokine release. Autoreactive CD4+ T cells, including Th17 subsets, produce pro-inflammatory cytokines like IFN-γ, promoting tissue destruction as observed in rheumatoid arthritis where IFN-γ drives synovial inflammation. CD8+ T cells contribute through perforin- and granzyme-mediated cytotoxicity, while a declining ratio of Tregs to effector T cells exacerbates this pathology during disease propagation.^[25]^[26] The inflammation cascade is triggered by immune complexes formed from autoantibodies and self-antigens, activating the complement system and engaging Fc receptors on innate immune cells. Complement activation, marked by C3 deposition in affected tissues like inflamed joints in rheumatoid arthritis, amplifies inflammation and recruits more immune effectors. Chronic infiltration of lymphocytes and macrophages sustains this cycle, leading to progressive tissue damage through persistent cytokine production and extracellular matrix degradation.^[25]^[26]

Role of Immune Cells and Cytokines

Autoreactive B cells play a central role in autoimmune diseases by producing autoantibodies that target self-antigens, leading to immune complex formation and tissue damage. These B cells escape normal tolerance mechanisms and differentiate into plasma cells that secrete pathogenic antibodies, such as rheumatoid factor in rheumatoid arthritis or anti-nuclear antibodies in systemic lupus erythematosus.^[27] In response to self-antigens, autoreactive B cells also act as antigen-presenting cells, amplifying T cell activation and sustaining chronic inflammation.^[28] T helper 17 (Th17) cells contribute to autoimmune pathology by promoting inflammation through the secretion of interleukin-17 (IL-17), which recruits neutrophils and stimulates the production of other pro-inflammatory mediators. In diseases like multiple sclerosis and psoriasis, Th17 cells drive tissue-specific damage by enhancing endothelial permeability and chemokine expression, exacerbating lesion formation.^[29] Regulatory T cells (Tregs), which normally suppress autoreactive responses via FOXP3-mediated mechanisms, become dysfunctional in autoimmunity, failing to inhibit effector T cells and allowing unchecked proliferation of pathogenic clones. This impairment is evident in conditions such as type 1 diabetes, where reduced Treg suppressive function correlates with beta-cell destruction.^[30] Cytokine imbalances further perpetuate autoimmunity, with pro-inflammatory cytokines like IL-17 and tumor necrosis factor-alpha (TNF-α) dominating over anti-inflammatory ones such as IL-10. In rheumatoid arthritis, elevated IL-17 and TNF-α from Th17 cells and macrophages promote synovial inflammation, cartilage degradation, and bone erosion, while diminished IL-10 exacerbates the lack of resolution.^[31] This skewed profile sustains a feed-forward loop of immune activation.^[32] Innate immune cells, including dendritic cells (DCs), aberrantly present self-antigens to T cells, bypassing tolerance and initiating adaptive responses. Immature or dysregulated DCs in autoimmune settings, such as in lupus, uptake apoptotic cells inefficiently, leading to prolonged exposure of autoantigens and priming of autoreactive T cells.^[33] Macrophages amplify this damage by polarizing toward a pro-inflammatory M1 phenotype, releasing reactive oxygen species and cytokines that recruit additional effectors and cause bystander tissue injury, as seen in inflammatory bowel disease. Recent studies have identified mitochondrial dysfunction in myeloid cells, including macrophages and DCs, as a central driver of this pro-inflammatory polarization, impairing oxidative phosphorylation and increasing reactive oxygen species production, which sustains autoimmunity across various diseases.^[34]^[35] Cross-talk between adaptive and innate immunity ensures the chronicity of autoimmunity, with activated T and B cells signaling back to DCs and macrophages via cytokines and ligands, reinforcing antigen presentation and effector function. This bidirectional interaction, involving IL-17 signaling to innate cells, creates a self-sustaining inflammatory milieu that resists resolution.^[36]

Causes and Risk Factors

Genetic Factors

Autoimmune diseases exhibit a significant genetic component, with heritability estimates ranging from 30% to 50% across various conditions, indicating that genetic factors contribute substantially to disease susceptibility while environmental influences play a complementary role.^[37] Twin studies underscore this heritability; for instance, monozygotic twins show concordance rates of 15% to 30% for multiple sclerosis, far exceeding the rates in dizygotic twins, which highlights the polygenic nature of genetic risk without full penetrance.^[38] These estimates derive from large-scale family and twin cohort analyses, emphasizing that while genetics predispose individuals, additional factors are required for disease manifestation.^[39] The strongest genetic associations with autoimmune diseases involve genes in the human leukocyte antigen (HLA) region, particularly MHC class II molecules that present self-peptides to T cells, thereby influencing immune tolerance.^[40] For example, HLA-DR4 alleles, specifically HLA-DRB1*04 variants, confer substantial risk for rheumatoid arthritis by altering peptide binding and presentation, leading to enhanced autoreactive T-cell activation.^[41] This HLA linkage is observed across multiple autoimmune conditions, where specific haplotypes modulate the risk by affecting the diversity and specificity of antigen presentation.^[42] Beyond HLA, non-HLA genes also contribute to autoimmunity through effects on immune signaling and regulation. The PTPN22 gene, encoding a tyrosine phosphatase involved in T-cell signaling, harbors variants like rs2476601 that impair negative regulation of T-cell activation, increasing susceptibility to diseases such as rheumatoid arthritis and systemic lupus erythematosus.^[43] Similarly, CTLA-4 variants, such as rs3087243, disrupt co-inhibitory signals essential for dampening T-cell responses, associating with increased risk in type 1 diabetes and other autoimmune disorders.^[44] These findings have informed the development of polygenic risk scores, which aggregate multiple genetic loci to quantify cumulative risk; for autoimmune diseases, such scores incorporating non-HLA variants explain a notable portion of heritability and aid in identifying high-risk individuals.^[45] Genome-wide association studies (GWAS) conducted in the 2020s have identified over 100 susceptibility loci for common autoimmune diseases, revealing shared genetic architecture across conditions like rheumatoid arthritis and multiple sclerosis.^[46] These loci often cluster in immune-related pathways, including T-cell activation and cytokine signaling, providing insights into common mechanisms of autoimmunity.^[47]

Environmental Triggers

Environmental triggers represent a diverse array of non-genetic factors that can precipitate or worsen autoimmune diseases in individuals with underlying genetic susceptibility. These external influences disrupt immune tolerance by promoting inflammation, altering barrier functions, or dysregulating hormonal and metabolic pathways, thereby facilitating the breakdown of self-tolerance. Key examples include disruptions in the gut microbiome due to dietary changes, exposure to ultraviolet radiation or specific pharmaceuticals, chronic psychological stress, and deficiencies in essential vitamins like vitamin D.^[48] Dietary patterns and the composition of the gut microbiome significantly influence autoimmune risk, particularly through mechanisms involving intestinal barrier integrity and microbial dysbiosis. In inflammatory bowel disease (IBD), dysbiosis—characterized by reduced abundance of anti-inflammatory bacteria such as Faecalibacterium prausnitzii and increased pathobionts like Fusobacterium nucleatum—drives local mucosal inflammation and contributes to systemic autoimmunity by enhancing gut permeability and promoting a Th17/Treg imbalance. Low dietary fiber intake exacerbates this by diminishing butyrate-producing bacteria, such as Roseburia, which degrade the colonic mucus barrier and increase translocation of proinflammatory molecules into circulation. Similarly, in celiac disease, gluten ingestion triggers zonulin release, a protein that disassembles tight junctions via CXCR3 and MyD88-dependent pathways, leading to leaky gut and antigen influx that activates T cells and perpetuates autoimmune enteropathy.^[49]^[49]^[50] Exposure to certain toxins and drugs can directly induce autoimmune responses, often through epigenetic modifications or oxidative stress. Ultraviolet (UV) light exposure, a well-established trigger for systemic lupus erythematosus (SLE), generates reactive oxygen species that inhibit DNA methyltransferase activity, causing T-cell hypomethylation and conversion to autoreactive phenotypes that promote lupus flares. Among pharmaceuticals, procainamide, an anti-arrhythmic agent, induces drug-induced lupus in up to 30% of users by inhibiting DNA methylation, leading to overexpression of lymphocyte function-associated antigen-1 (LFA-1) on CD4+ T cells and subsequent autoantibody production against histones. Symptoms typically resolve upon drug discontinuation, highlighting the reversible nature of this environmental trigger.^[51]^[52]^[52] Psychological stress and associated hormonal fluctuations further contribute to autoimmunity by dysregulating the hypothalamic-pituitary-adrenal (HPA) axis. Chronic stress impairs HPA axis negative feedback, resulting in glucocorticoid receptor resistance and altered cortisol dynamics—initially elevated levels followed by hypocortisolism—which skews cytokine profiles toward proinflammatory mediators like IL-6 and TNF-α while suppressing regulatory T cells and anti-inflammatory IL-10. This dysregulation weakens immune tolerance and accelerates disease progression in conditions such as SLE and rheumatoid arthritis. Estrogen fluctuations, often amplified by stress, exacerbate this by enhancing B-cell survival through BCL-2 upregulation and reducing negative selection of autoreactive B cells, thereby promoting immune complex deposition.^[53]^[53]^[54] Vitamin D deficiency emerges as a prominent environmental risk factor, particularly in regions with limited sunlight exposure. Low serum 25-hydroxyvitamin D levels correlate with increased onset of multiple sclerosis (MS), with prospective studies showing a 62% reduced risk at concentrations above 100 nmol/L; this association is strongest in northern latitudes, where reduced UVB radiation impairs endogenous vitamin D synthesis, leading to higher MS prevalence. Mechanistically, vitamin D modulates immune responses by suppressing Th17 cells and enhancing regulatory T cells, and its deficiency disrupts this balance, facilitating demyelination in genetically predisposed individuals. Mendelian randomization analyses confirm causality, estimating that a 50% increase in vitamin D reduces MS odds by approximately 50%.^[55]^[55]^[55]

Infections and Molecular Mimicry

Molecular mimicry is a key mechanism by which infections can initiate autoimmune diseases, occurring when microbial antigens share structural or sequence similarities with host self-antigens, leading to cross-reactive immune responses that target self-tissues.^[56] In this process, antibodies or T cells generated against a pathogen mistakenly attack host proteins due to epitope homology, breaching immune tolerance.^[57] A prominent example involves Epstein-Barr virus (EBV), where the viral protein EBNA-1 exhibits sequence similarity to myelin basic protein (MBP), a key component of central nervous system myelin.^[58] This mimicry is implicated in multiple sclerosis (MS), as EBV-specific CD8+ T cells cross-react with MBP, contributing to demyelination in genetically susceptible individuals.^[58] Specific bacterial and viral infections exemplify this mechanism. Group A Streptococcus in acute rheumatic fever triggers autoantibodies that cross-react with cardiac myosin due to shared epitopes between streptococcal M proteins and heart tissue antigens.^[59] Similarly, coxsackievirus B4, associated with type 1 diabetes, shares homologous sequences in its protein 2C with glutamic acid decarboxylase 65 (GAD65), an islet autoantigen, promoting beta-cell destruction.^[60] Post-infectious autoimmunity often follows pathogen clearance, where molecular mimicry persists or combines with other effects. In Guillain-Barré syndrome (GBS), Campylobacter jejuni lipopolysaccharides mimic gangliosides on peripheral nerves, eliciting cross-reactive antibodies that cause neuropathy.^[61] Bystander activation complements this by non-specifically stimulating autoreactive T cells through inflammatory cytokines released during viral clearance, amplifying self-directed responses without direct antigen mimicry.^[62] Evidence from animal models supports these pathways. In experimental autoimmune encephalomyelitis (EAE), a rodent model of MS, immunization with viral peptides mimicking myelin antigens induces disease, demonstrating how infectious triggers can drive CNS autoimmunity via cross-reactivity.^[63]

Hormonal and Gender Influences

Autoimmune diseases disproportionately affect females, with approximately 78% of cases occurring in women across various organ systems and disease types.^[64] This gender disparity is largely attributed to the immunomodulatory effects of sex hormones, where estrogen promotes immune activation and testosterone exerts suppressive influences.^[65] Estrogen enhances the survival and function of B cells, which are critical in humoral immunity and autoantibody production. By upregulating anti-apoptotic proteins such as Bcl-2, estrogen allows autoreactive B cells to evade tolerance mechanisms and persist, thereby contributing to autoimmune pathogenesis.^[66] In contrast, testosterone suppresses autoimmune responses by inhibiting both cellular and humoral immunity, increasing the threshold for autoimmunity development through anti-inflammatory effects on immune cells.^[67] Hormonal fluctuations across life stages further influence disease activity. In systemic lupus erythematosus (SLE), estrogen surges during pregnancy often trigger disease flares, while rheumatoid arthritis (RA) typically remits during pregnancy but exacerbates postpartum.^[68] Menopause, characterized by declining estrogen levels, is associated with RA onset or worsening, highlighting the protective role of premenopausal hormonal balance in some autoimmune conditions.^[69] Genetic factors related to sex chromosomes also contribute to female predisposition. Females possess two X chromosomes, one of which undergoes random inactivation to balance gene dosage with males; however, skewed X-chromosome inactivation can lead to the escape of autoimmunity-associated genes from silencing, promoting autoreactive immune responses.^[70] This phenomenon is observed at higher frequencies in females with autoimmune thyroid diseases, underscoring its role in gender-biased autoimmunity.^[71] Animal models provide mechanistic insights into these influences. In female mice prone to SLE-like disease, ovariectomy—which removes ovarian estrogen sources—delays autoantibody production and reduces disease severity, demonstrating estrogen's pro-autoimmune effects.^[72]

Clinical Presentation

General Symptoms

Autoimmune diseases often present with a constellation of non-specific symptoms that reflect underlying systemic inflammation and immune dysregulation. Fatigue and malaise are among the most prevalent complaints, affecting 70-90% of patients across various autoimmune conditions due to chronic inflammatory processes that disrupt energy metabolism and sleep patterns.^[73] This persistent exhaustion can significantly impair daily functioning and quality of life, often persisting even in the absence of active disease flares.^[74] Low-grade fevers and unintended weight loss are also common early indicators, resulting from the release of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), which elevate body temperature and induce a hypermetabolic state.^[75] ^[76] These fevers are typically recurrent and mild, while weight loss arises from increased energy expenditure, reduced appetite, and gastrointestinal disturbances linked to inflammation, sometimes leading to cachexia in severe cases.^[77] ^[78] Musculoskeletal pain and stiffness frequently emerge as initial presentations, manifesting as joint aches, muscle tenderness, or generalized discomfort that worsens with inactivity, particularly in the morning.^[78] These symptoms stem from inflammatory infiltration of connective tissues and are reported in a majority of patients with conditions like rheumatoid arthritis or systemic lupus erythematosus.^[79] Visible skin and mucosal changes, such as rashes, photosensitivity, or oral ulcers, serve as early outward signs in many cases, highlighting the immune system's attack on epithelial barriers.^[80] These manifestations, including erythematous plaques or recurrent aphthous ulcers, can precede other symptoms and aid in prompting clinical evaluation.^[81]

Patterns of Onset and Progression

Autoimmune diseases display diverse patterns of onset, ranging from acute to chronic, which influence the initial clinical course and subsequent management challenges. Acute onset is characterized by the rapid emergence of severe symptoms, often within days to weeks, as observed in type 1 diabetes mellitus, where acute hyperglycemia and ketoacidosis develop suddenly after significant beta-cell destruction.^[82] In contrast, chronic or insidious onset predominates in many systemic autoimmune conditions, with nonspecific symptoms like fatigue and mild joint pain accumulating gradually over months or years before full diagnostic criteria are met; rheumatoid arthritis exemplifies this, where autoantibodies such as anti-citrullinated protein antibodies appear up to five years prior to overt polyarthritis.^[82] Systemic lupus erythematosus also typically follows an insidious trajectory, with antinuclear antibodies detectable years before the onset of multisystem involvement.^[28] These patterns highlight how the tempo of onset can delay diagnosis in chronic cases, complicating early intervention.^[83] Progression in autoimmune diseases often follows relapsing-remitting or steadily progressive trajectories, reflecting underlying immune dysregulation dynamics. Relapsing-remitting patterns are common, featuring episodic flares of heightened symptoms interspersed with periods of partial or complete remission; multiple sclerosis most frequently presents this way, with about 85% of cases initially showing relapses such as optic neuritis followed by recovery phases, though many transition to secondary progressive disease over time.^[82] Systemic lupus erythematosus similarly exhibits relapsing-remitting flares affecting various systems, driven by recurrent autoantibody surges.^[28] Progressive patterns, conversely, involve continuous symptom worsening without distinct relapses, as in primary progressive multiple sclerosis, where neurological deficits accumulate steadily from onset, or in certain vasculitic syndromes like giant cell arteritis, which can lead to unrelenting vascular inflammation.^[28] These trajectories underscore the heterogeneous natural history across autoimmune disorders, with relapsing forms allowing intermittent stability while progressive ones portend inexorable decline.^[83] Flares, defined as acute exacerbations of disease activity, are pivotal in relapsing-remitting autoimmune conditions and can be triggered by external or internal factors that disrupt immune homeostasis. Infections represent a primary trigger, frequently preceding flares in multiple sclerosis and systemic lupus erythematosus by activating molecular mimicry or cytokine storms.^[84] Psychological stress and environmental exposures, such as smoking or ultraviolet light, also precipitate flares by modulating immune responses, as evidenced in rheumatoid arthritis where stress correlates with increased inflammatory markers.^[85] Non-adherence to lifestyle factors or subclinical immune shifts can further exacerbate cycles, amplifying symptom intensity during vulnerable periods.^[86] Long-term outcomes in autoimmune diseases vary widely but often include risks of cumulative damage, disability, or remission depending on the progression pattern and onset timing. In relapsing-remitting diseases like multiple sclerosis, untreated progression may lead to irreversible neurological disability in up to 50% of cases within 15-20 years, though spontaneous remissions occur in some.^[28] Progressive forms, such as primary progressive multiple sclerosis, are associated with earlier and more severe functional impairment, including mobility loss.^[83] Early-onset diseases, including systemic lupus erythematosus in adolescents, confer poorer prognoses with doubled mortality rates due to prolonged exposure to flares and complications like renal involvement.^[83] Overall, without addressing the underlying autoimmunity, many conditions culminate in chronic morbidity or organ dysfunction, though a subset achieves sustained remission through immune quiescence.^[82]

Organ-Specific Manifestations

Autoimmune diseases often target specific organs or tissues, leading to localized inflammation and functional impairment that can significantly affect quality of life. These manifestations arise from aberrant immune responses directed against self-antigens in particular anatomical sites, resulting in tissue damage that varies by the affected system. While some autoimmune conditions are strictly organ-specific, others exhibit overlapping features, but the focus here is on prototypical presentations in key body systems. In the musculoskeletal system, autoimmune-mediated joint inflammation typically involves synovial membrane hyperplasia, pannus formation, and erosive changes to articular cartilage and bone, leading to chronic pain, stiffness, and reduced mobility.^[87] Myositis, or inflammation of skeletal muscle fibers, manifests as progressive proximal muscle weakness, fatigue, and elevated serum muscle enzymes, often impairing daily activities such as climbing stairs or rising from a seated position.^[88] Dermatological involvement in autoimmunity frequently presents with erythematous rashes, including photosensitive malar erythema or discoid lesions that cause hyperpigmentation and scarring upon healing.^[89] Alopecia, particularly in systemic autoimmune contexts, results from immune attack on hair follicles, leading to non-scarring patchy hair loss that can progress to diffuse thinning or total scalp involvement.^[90] Neurological manifestations of autoimmunity often include demyelination of central or peripheral nerves, disrupting myelin sheaths and impairing nerve conduction, which results in sensory loss, motor deficits, or coordination problems.^[91] This can extend to peripheral neuropathy with symptoms like paresthesia, numbness, and autonomic dysfunction, or central involvement causing cognitive impairments such as memory deficits and executive dysfunction.^[92] Gastrointestinal autoimmunity targets mucosal linings, inducing chronic inflammation that erodes the epithelial barrier and submucosa, often presenting with diarrhea, abdominal pain, and weight loss.^[93] Malabsorption syndromes arise from villous atrophy and impaired nutrient uptake in the small intestine, leading to deficiencies in vitamins, minerals, and proteins that exacerbate systemic effects.^[93]

Diagnosis

Clinical History and Examination

The evaluation of suspected autoimmune disease begins with a comprehensive clinical history and physical examination, which are foundational for identifying patterns suggestive of autoimmunity and guiding further diagnostic steps.^[94] A detailed history focuses on family history of autoimmune conditions, as these disorders often cluster within families due to shared genetic predispositions, with first-degree relatives facing approximately a 10- to 20-fold increased risk for diseases such as systemic lupus erythematosus (SLE) and Sjögren's syndrome.^[95]^[96] The symptom timeline is meticulously documented to capture the onset and progression, which may be insidious in conditions like rheumatoid arthritis (RA) or autoimmune hepatitis, often starting with nonspecific complaints such as fatigue, low-grade fever, or weight loss.^[26] Trigger exposures are probed, including prior infections, medication use (e.g., antiarrhythmic drugs implicated in drug-induced lupus), environmental factors like smoking, or stressors, which can precipitate autoimmune responses through mechanisms such as molecular mimicry.^[26] Physical examination reveals characteristic signs that provide diagnostic clues. Joint swelling, particularly symmetric involvement of small joints, is a hallmark of RA and may also occur in spondyloarthropathies, often accompanied by tenderness and warmth.^[26] Skin lesions vary by disease but are prominent in many; for instance, the malar rash of SLE or erythematous, scaly plaques in psoriasis signal cutaneous autoimmunity.^[26] Lymphadenopathy, indicating lymphoid hyperplasia, is a common finding in systemic diseases like SLE, reflecting broader immune activation.^[26] These signs, when present, underscore the need for a targeted organ systems review to detect subtle abnormalities. Red flags during history and examination include evidence of multi-system involvement, which suggests severe systemic autoimmunity and warrants urgent evaluation; examples include concurrent renal, pulmonary, or neurological symptoms in SLE or widespread organ damage in sarcoidosis.^[26] Patient-reported outcomes enhance this assessment, with tools like the Visual Analog Scale (VAS) used to quantify pain severity.^[97] This subjective input, combined with objective findings, helps delineate the disease's impact on daily function.^[94]

Laboratory Investigations

Laboratory investigations play a crucial role in confirming autoimmune activity by detecting autoantibodies, inflammatory processes, and secondary effects on blood cells and organ function, often complementing clinical history findings. These tests typically involve blood samples to identify specific markers of immune dysregulation and tissue damage associated with various autoimmune diseases.^[98] Autoantibody panels are essential for disease-specific diagnosis. The antinuclear antibody (ANA) test screens for systemic lupus erythematosus (SLE), with over 95% sensitivity but about 60% specificity, as it detects antibodies targeting cell nuclei and is also positive in conditions like Hashimoto's thyroiditis.^[98] Anti-double-stranded DNA (anti-dsDNA) antibodies offer higher specificity (around 95%) for SLE, with 70% sensitivity, and their levels correlate with disease activity, particularly in lupus nephritis.^[98] For rheumatoid arthritis (RA), rheumatoid factor (RF) is detected in approximately 70% of cases with similar sensitivity and specificity, though it can occur in healthy individuals; anti-cyclic citrullinated peptide (anti-CCP) antibodies provide greater specificity (about 95%) and predict more severe, erosive disease.^[98] Inflammatory markers help assess disease activity and response to treatment. Erythrocyte sedimentation rate (ESR) is a non-specific indicator of inflammation, commonly elevated in active RA and SLE, but it responds slowly to therapy changes.^[98] C-reactive protein (CRP) levels, which rise more acutely with inflammation (typically >1.0 mg/dL in active disease), are useful for monitoring flares in conditions like RA and SLE, offering better responsiveness than ESR.^[98] A complete blood count (CBC) often reveals hematologic abnormalities due to autoimmune-mediated suppression. Anemia, usually normochromic and normocytic, reflects chronic inflammation in diseases such as SLE and RA.^[98] Leukopenia, particularly lymphopenia, is frequent in SLE, resulting from bone marrow suppression or increased peripheral destruction by autoantibodies.^[99] Specific assays target organ involvement to guide management. In Hashimoto's thyroiditis, thyroid peroxidase (TPO) antibodies are positive in over 90% of cases, confirming autoimmune etiology, while thyroglobulin antibodies appear in 50-80%.^[100] For renal involvement, serum creatinine levels are monitored to evaluate kidney function in SLE and other systemic autoimmune diseases, with elevations indicating potential lupus nephritis or glomerular damage.^[101]

Imaging and Biopsy Techniques

Magnetic resonance imaging (MRI) and computed tomography (CT) scans are essential for visualizing structural and inflammatory changes in autoimmune diseases. In multiple sclerosis (MS), MRI is the gold standard for detecting demyelinating plaques in the brain and spinal cord, revealing hyperintense lesions on T2-weighted images that indicate active inflammation and axonal damage.^[102] In rheumatoid arthritis (RA), MRI identifies synovial inflammation, bone erosions, and joint effusions with high sensitivity, often earlier than plain radiographs, while CT provides detailed assessment of bone destruction and joint space narrowing.^[103] Whole-body MRI has emerged as a valuable tool in rheumatology for evaluating multifocal involvement in systemic autoimmune conditions, allowing non-invasive monitoring of disease progression and treatment response.^[103] Ultrasound imaging offers a non-invasive, real-time method to assess soft tissue and glandular abnormalities in autoimmune diseases. In Sjögren's syndrome, salivary gland ultrasound detects hypoechoic areas, glandular enlargement, and heterogeneous echotexture indicative of lymphocytic infiltration, with features like the "salt-and-pepper" pattern correlating with disease severity.^[104] Advanced ultrasound techniques, such as elastography, further evaluate tissue stiffness in affected salivary glands, aiding in early diagnosis and differentiation from other sialadenitis causes.^[105] For autoimmune thyroiditis, thyroid ultrasound reveals hypoechoic, heterogeneous parenchyma and increased vascularity, helping identify nodules or atrophy associated with Hashimoto's thyroiditis.^[106] Biopsy procedures provide histological confirmation of autoimmune damage by examining tissue samples for immune cell infiltrates and pathological features. Skin biopsies, often performed via punch technique, demonstrate interface dermatitis and perivascular lymphocytic infiltrates in conditions like lupus erythematosus or dermatomyositis.^[107] Kidney biopsies, obtained percutaneously under ultrasound guidance, reveal glomerulonephritis patterns such as mesangial proliferation or crescents in lupus nephritis and other autoimmune glomerulopathies, guiding targeted immunosuppression.^[108] Muscle biopsies, typically open or needle-based, show endomysial inflammation, perifascicular atrophy, and MHC class I upregulation in inflammatory myopathies like polymyositis, distinguishing autoimmune from non-immune muscle disorders.^[109] Positron emission tomography (PET) scans, particularly when combined with CT (PET/CT), are increasingly utilized for detecting metabolic activity in autoimmune vasculitides. In large vessel vasculitis such as giant cell arteritis (GCA) and Takayasu arteritis, 18F-fluorodeoxyglucose (18F-FDG) PET/CT highlights hypermetabolic vessel walls due to inflammatory cell uptake, enabling whole-body assessment of disease extent and monitoring therapeutic efficacy.^[110] Emerging applications by 2025 include its role in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, where PET/CT identifies occult organ involvement with high sensitivity, though specificity requires correlation with clinical findings.^[111]

Differential Diagnosis

Differentiating autoimmune diseases from other conditions is crucial due to overlapping clinical features, as autoimmune disorders often mimic infectious, neoplastic, or metabolic processes. For instance, acute viral infections can present with arthralgias and fever resembling rheumatoid arthritis (RA), while bacterial endocarditis may imitate systemic lupus erythematosus (SLE) through multisystem involvement. Common mimics include infections, such as viral arthritis from parvovirus B19 or hepatitis, which can cause symmetric joint swelling similar to early RA but typically resolve spontaneously without chronic progression. Malignancies, particularly paraneoplastic syndromes associated with lymphomas or solid tumors, may produce autoimmune-like manifestations including dermatomyositis or vasculitis, necessitating exclusion through imaging and tumor markers. Metabolic disorders, like hemochromatosis or thyroid dysfunction, can also simulate autoimmune arthropathies by inducing joint pain and fatigue. Diagnostic algorithms aid in exclusion by emphasizing specific criteria; the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification for RA requires at least 6 points from joint involvement, serology (e.g., rheumatoid factor or anti-CCP antibodies), and acute-phase reactants, helping to rule out infectious or degenerative arthritides. Similarly, for SLE, the 2019 ACR/EULAR criteria incorporate entries like antinuclear antibodies, leukopenia, and renal involvement to distinguish it from infectious mimics such as subacute bacterial endocarditis. These frameworks integrate clinical history, laboratory tests, and imaging to prioritize autoimmune etiology.

Management and Treatment

Pharmacological Therapies

Pharmacological therapies for autoimmune diseases primarily aim to alleviate symptoms such as pain and inflammation while modifying disease progression to prevent organ damage. These treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, corticosteroids, and disease-modifying antirheumatic drugs (DMARDs), are often initiated based on clinical manifestations like joint swelling in rheumatoid arthritis (RA) or systemic flares in systemic lupus erythematosus (SLE).^[112]^[113] NSAIDs and analgesics provide rapid symptom relief for pain and inflammation, particularly in early stages of conditions like RA or mild SLE. In RA, NSAIDs such as ibuprofen or naproxen are used to reduce joint pain and swelling, improving function within weeks, though they do not alter the underlying disease course.^[112] For SLE, NSAIDs like ibuprofen are recommended for mild arthralgias or serositis, offering short-term control without disease-modifying effects.^[114] Analgesics, such as acetaminophen, serve as adjuncts for pain management in both RA and SLE until more potent therapies take effect, avoiding the gastrointestinal risks associated with chronic narcotic use.^[112] Corticosteroids are employed for acute flares due to their potent anti-inflammatory properties and rapid onset. In RA, low-dose oral prednisone (5-10 mg daily) or intra-articular injections are used as bridging therapy alongside DMARDs to control severe symptoms, with guidelines recommending avoidance of long-term use (≥3 months) to minimize risks.^[112]^[115] For SLE, high-dose intravenous pulse methylprednisolone (typically 500-1000 mg/day for 3 days) is recommended for active disease such as lupus nephritis, followed by oral prednisone tapered to ≤5 mg/day for maintenance to limit exposure.^[116] Tapering protocols, such as gradual reduction over weeks to months, are standard to prevent rebound flares while managing side effects.^[113] DMARDs represent the cornerstone for long-term disease modification in autoimmune conditions. Methotrexate is the first-line conventional synthetic DMARD (csDMARD) for RA, administered orally or subcutaneously at 12.5-25 mg weekly, with titration to ≥15 mg/week within 4-6 weeks to achieve remission or low disease activity; it slows joint damage but requires monitoring for hepatotoxicity and infections.^[112]^[115] In SLE, hydroxychloroquine is recommended for all patients at a target dose of 5 mg/kg real body weight daily (typically 200-400 mg/day) to reduce flares and improve survival, with baseline and periodic ophthalmologic screening for retinal toxicity.^[116]^[114] Dosage adjustments and monitoring are essential to balance efficacy and safety, particularly with long-term use. For corticosteroids, baseline bone mineral density assessment via DEXA scan is advised for at-risk patients (e.g., those ≥40 years or with prior fractures), followed by annual fracture risk evaluation using tools like FRAX, alongside calcium and vitamin D supplementation to mitigate osteoporosis, which affects up to 40% of long-term users through bone loss and increased fracture risk within 6-12 months.^[117] In RA patients on methotrexate, liver function tests are monitored every 4-8 weeks, especially in those with nonalcoholic fatty liver disease, while SLE patients on hydroxychloroquine undergo annual retinal exams after five years of use.^[115]^[116]

Immunomodulatory and Biologic Agents

Immunomodulatory and biologic agents target specific components of the immune system to restore balance in autoimmune diseases, offering precision interventions for severe or refractory cases. These therapies, including monoclonal antibodies and small-molecule inhibitors, modulate dysregulated pathways such as B-cell activity, cytokine signaling, and T-cell responses, often achieving deeper and more sustained remission than traditional immunosuppressants.^[118] Monoclonal antibodies exemplify targeted immune modulation by binding to surface markers or soluble factors. Rituximab, an anti-CD20 monoclonal antibody, depletes CD20-positive B cells, thereby reducing autoreactive antibody production and B-cell-mediated inflammation in conditions like antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. In clinical trials such as RAVE and RITUXVAS, rituximab achieved remission rates of 64% to 76% at 6 months in patients with granulomatosis with polyangiitis or microscopic polyangiitis, with maintenance therapy lowering relapse rates to 15-17%.^[119] Similarly, infliximab, a chimeric anti-tumor necrosis factor (TNF) monoclonal antibody, neutralizes TNF-α to suppress pro-inflammatory cascades in Crohn's disease, an autoimmune inflammatory bowel disorder. It induces partial or complete clinical response in 67% of moderate-to-severe cases, with 68% of patients maintaining remission beyond 52 weeks.^[120] Janus kinase (JAK) inhibitors represent another class of immunomodulatory agents that interrupt intracellular signaling downstream of multiple cytokines. Tofacitinib, a selective JAK1/JAK3 inhibitor, blocks pathways involved in T-cell activation and pro-inflammatory cytokine production, such as interleukin-6 and interferon-γ, in rheumatoid arthritis (RA). Phase 3 trials (ORAL series) demonstrated American College of Rheumatology 20% improvement (ACR20) response rates of 52-66% at 3-6 months, with disease activity score (DAS28) remission rates of 8-16% depending on dose and background therapy.^[121] Efficacy data from biologic agents in RA highlight their impact, with recent real-world registries reporting remission rates of 40-60% among treated patients. In the FIRST Registry's 5-year analysis of over 5,000 cases, TNF inhibitors achieved 41.8% remission at 6 months and up to 53.9% at 60 months in biologic-naïve patients, underscoring sustained benefits in treat-to-target strategies.^[122] Emerging biologic approaches, such as chimeric antigen receptor (CAR) T-cell therapies, offer potential for immune reset in refractory autoimmunity. Anti-CD19 CAR T cells target and deplete pathogenic B cells in systemic lupus erythematosus (SLE), with early trials showing durable remission exceeding 1 year without ongoing immunosuppression in refractory cases. Post-2023, the U.S. FDA granted Fast Track Designation to investigational CAR T therapies like CABA-201 for SLE and lupus nephritis, accelerating development for severe, treatment-resistant disease.^[123]^[124]

Supportive and Surgical Interventions

Supportive interventions in autoimmune diseases focus on managing complications, preserving organ function, and improving quality of life without directly targeting the immune response. These approaches are essential for addressing symptoms arising from disease progression, such as joint damage or organ failure, and are often integrated into multidisciplinary care plans.^[125]^[126] Physical therapy plays a key role in maintaining joint mobility and function in autoimmune arthritides like rheumatoid arthritis (RA), where it helps reduce pain, strengthen supporting muscles, and prevent deformities through targeted exercises and modalities such as hydrotherapy or electrical stimulation. In multiple sclerosis (MS), rehabilitation following acute flares involves physical therapy to restore gait, balance, and coordination via resistance training and kinesiotherapy, enabling patients to regain independence and mitigate fatigue. These interventions are tailored to individual limitations and can significantly enhance daily functioning when initiated early.^[127]^[125]^[128]^[129] Surgical options are reserved for severe, refractory cases to alleviate symptoms and restore function. In Graves' disease, total thyroidectomy serves as a definitive treatment by removing the overactive thyroid gland, rapidly resolving hyperthyroidism with low complication rates when performed by experienced surgeons, though it requires lifelong hormone replacement. For advanced RA, joint replacement surgeries, such as total knee or hip arthroplasty, effectively address joint destruction by resurfacing damaged areas with prosthetic implants, improving mobility and reducing pain in late-stage disease. These procedures are indicated when conservative measures fail and carry risks like infection, but outcomes have improved with modern techniques.^[130]^[131]^[126]^[132] Organ support measures are critical for life-threatening complications in autoimmune diseases. Dialysis, particularly hemodialysis, is used in lupus nephritis when kidney function declines to end-stage renal disease, filtering waste and excess fluid to stabilize patients and potentially allowing some recovery of renal function in up to 28% of cases. Plasmapheresis, or therapeutic plasma exchange, addresses acute crises in conditions like MS relapses or severe autoimmune neurological disorders by rapidly removing pathogenic antibodies from the blood, providing symptom relief as an adjunct to other therapies. These extracorporeal techniques bridge acute episodes and support organ preservation until stability is achieved.^[133]^[134]^[135]^[136] Palliative care is increasingly recognized for patients with progressive autoimmune diseases facing end-stage organ failure, emphasizing symptom management, psychosocial support, and advance care planning to optimize quality of life amid chronic burdens like pain and debility in RA or lupus. In such scenarios, it integrates with ongoing treatments to address non-malignant suffering, reducing hospitalizations and improving end-of-life experiences, though utilization remains low in rheumatology settings.^[137]^[138]^[139]

Lifestyle and Preventive Measures

Lifestyle modifications play a crucial role in managing autoimmune diseases by reducing inflammation, mitigating triggers, and potentially preventing flares. Adopting an anti-inflammatory diet, such as the Mediterranean diet rich in fruits, vegetables, whole grains, and omega-3 fatty acids from fish, has been associated with lower disease activity and reduced risk in conditions like rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). For instance, higher adherence to the Mediterranean diet correlates with a decreased incidence of RA, as evidenced by longitudinal cohort studies. In celiac disease, a specific autoimmune disorder, strict gluten avoidance is essential to prevent intestinal damage and subsequent flares, allowing mucosal healing and symptom resolution.^[140]^[141]^[142] Regular exercise and stress management techniques further support immune balance and flare prevention. Low-impact activities like yoga have demonstrated benefits in SLE, improving quality of life, reducing fatigue, and potentially decreasing flare frequency by modulating stress responses and inflammation. Clinical studies indicate that yoga practice can lower cortisol levels and enhance overall well-being in patients with lupus, without exacerbating symptoms when tailored appropriately. Similarly, mindfulness-based stress reduction complements these efforts by alleviating psychological triggers that may precipitate autoimmune exacerbations.^[143]^[144] Preventive measures also include targeted vaccinations and environmental avoidance strategies. Inactivated influenza vaccines are recommended annually for individuals with autoimmune diseases to guard against infections that could trigger flares, as they are generally safe and effective without increasing disease activity. For photosensitive conditions like SLE and dermatomyositis, rigorous sun protection—such as broad-spectrum sunscreen (SPF 30+), protective clothing, and limiting midday exposure—is vital to prevent UV-induced skin lesions and systemic flares, affecting 40-70% of lupus patients.^[145]^[146]^[147] Early screening for at-risk individuals, particularly family members with genetic predispositions, enables proactive monitoring. Testing for autoantibodies, such as antinuclear antibodies (ANA) or disease-specific markers like anti-tissue transglutaminase in celiac disease, can detect preclinical autoimmunity, allowing timely interventions to halt progression. Guidelines recommend periodic antibody screening in first-degree relatives of those with autoimmune conditions, especially type 1 diabetes or SLE, to identify elevated risk early.^[148]^[149]

Epidemiology

Prevalence and Incidence

Autoimmune diseases collectively represent a significant global health burden, with estimates indicating that they affect approximately 4-8% of the population in developed countries, translating to a lifetime prevalence of around 5% in many regions. In the United States, recent analyses (as of 2024) suggest that about 15 million individuals, or 4.6% of the population, live with at least one diagnosed autoimmune disease, though broader estimates including undiagnosed cases indicate up to 50 million affected (8%).^[3]^[1] Globally, the cumulative impact is estimated to affect 5-10% of the population in industrialized nations, underscoring the widespread nature of these conditions.^[150]^[151] Women are disproportionately affected, with a female-to-male ratio of approximately 4:1 across most autoimmune diseases, contributing to the overall burden. Disease-specific incidence rates vary, but rheumatoid arthritis (RA) serves as a representative example, with an annual incidence of about 40 cases per 100,000 individuals in the United States and northern Europe. Similarly, multiple sclerosis (MS) has an incidence of roughly 5-7 cases per 100,000 in temperate zones, highlighting regional patterns within this category.^[65]^[152]^[153] Incidence and prevalence of autoimmune diseases have shown rising trends, with annual increases estimated at 3-12% worldwide, potentially driven by improved diagnostics and environmental factors. Estimates suggest that around 24 million people in the United States and a comparable number in the European Union—totaling over 50 million in these regions—are affected, reflecting continued growth in cases.^[6]^[154]^[155]

Demographic and Geographic Variations

Autoimmune diseases exhibit notable variations by age, with peak onset commonly occurring between 20 and 50 years, though this range can differ by specific condition; for example, rheumatoid arthritis often begins between 30 and 55 years, while systemic lupus erythematosus (SLE) incidence peaks in the 20-50 year range among women.^[156]^[157] These diseases disproportionately affect females, with a female-to-male ratio frequently surpassing 4:1, attributed to hormonal and genetic factors influencing immune responses.^[158] In pediatric populations, autoimmune conditions like juvenile idiopathic arthritis (JIA) represent a significant subset, with systemic-onset JIA comprising 10-20% of all JIA cases and onset before age 16.^[159]^[160] Ethnic disparities are evident in the prevalence of specific autoimmune diseases; SLE is two to three times more prevalent among African Americans compared to White individuals, often presenting with more severe manifestations and earlier onset.^[161] Similarly, celiac disease shows higher rates among individuals of European descent, with prevalence reaching 0.8% in Europe and Oceania versus lower figures in Asia (0.6%) and Africa (0.5%).^[162]^[163] Geographically, autoimmune diseases display a latitude gradient, particularly for multiple sclerosis (MS), where prevalence increases from low rates near the equator to higher rates at higher latitudes toward the poles, potentially linked to reduced sunlight exposure and vitamin D synthesis.^[164]^[55] This pattern holds across global studies, with MS incidence rising in tandem with distance from the equator, supporting a role for environmental factors like ultraviolet radiation in disease etiology.^[165]^[166] Socioeconomic factors exacerbate morbidity in autoimmune diseases, as lower income and lack of insurance create barriers to timely diagnosis and treatment, leading to poorer outcomes in underserved populations.^[167] For instance, individuals in low-income areas face delayed care for conditions like SLE, resulting in higher rates of organ damage and complications independent of clinical severity.^[168] Neighborhood deprivation has also been associated with elevated risks of autoimmune disorders, underscoring the interplay between social determinants and disease progression.^[169]

Temporal Trends and Risk Factors

The prevalence of autoimmune diseases has shown a marked upward trend over recent decades, with estimates indicating a significant rise in diagnoses since the 1980s attributable to improved diagnostic awareness, increased longevity allowing more time for disease manifestation, and enhanced medical surveillance.^[170] For instance, global studies report annual increases in incidence and prevalence ranging from 3% to 19.1%, reflecting a doubling or more in affected populations for several conditions like rheumatoid arthritis and systemic lupus erythematosus over this period.^[171]^[154] This escalation is not uniform but demonstrates consistent growth across diverse autoimmune disorders, underscoring the role of temporal epidemiological shifts.^[172] Contemporary environmental and lifestyle factors have further contributed to these trends, particularly in urban settings where pollution and urbanization correlate with heightened risks for asthma-associated autoimmunities and other inflammatory conditions. Air pollution, including particulate matter and xenobiotics, has been linked to immune dysregulation that exacerbates autoimmune responses, with urban dwellers showing elevated rates compared to rural populations.^[173]^[174] These modifiable risks highlight how modern societal changes, such as reduced exposure to diverse microbes in sanitized urban environments (the "hygiene hypothesis"), may disrupt immune tolerance and drive the observed rises.^[175] Projection models forecast a continued global upsurge in autoimmune disease burden by 2030, driven primarily by aging populations that amplify cumulative risk exposure and disease expression.^[176] The World Health Organization projects that by 2030, one in six individuals worldwide will be aged 60 or older, a demographic shift that will likely intensify autoimmune prevalence given the association between advanced age and immune senescence.^[177] These trends carry significant public health implications, prompting the development of targeted screening programs for high-risk groups, such as those with family history or environmental exposures, to enable early intervention and mitigate long-term morbidity.^[178]^[179]

Research Directions

Emerging Hypotheses

Recent research has advanced the understanding of autoimmune disease origins by emphasizing dynamic interactions between the host and environment, moving beyond static genetic models. Emerging hypotheses highlight how perturbations in microbial communities, epigenetic landscapes, early-life exposures, and post-translational modifications contribute to immune dysregulation, often integrating genetic predispositions with external triggers. These theories, supported by post-2020 studies, underscore the multifactorial nature of autoimmunity and inform potential preventive strategies. One prominent hypothesis posits that microbiome dysbiosis, particularly in the gut, acts as a key trigger for autoimmune diseases by disrupting immune homeostasis and promoting inflammation. In inflammatory bowel disease (IBD), a classic autoimmune condition, gut dysbiosis is a hallmark feature observed in the majority of patients, characterized by reduced microbial diversity and overgrowth of proinflammatory taxa such as Proteobacteria. This imbalance compromises the intestinal barrier, allowing microbial products to translocate and activate systemic immune responses, thereby exacerbating autoimmunity in conditions like IBD and beyond. Clinical trials exploring fecal microbiota transplantation (FMT) to restore eubiosis have shown promising results, with meta-analyses indicating higher remission rates in ulcerative colitis patients compared to controls, though long-term efficacy remains under investigation. Epigenetic modifications represent another evolving framework, where environmental factors induce heritable changes in gene expression without altering DNA sequences, thereby unmasking autoimmune susceptibility. In systemic lupus erythematosus (SLE), DNA hypomethylation—often triggered by exposures like ultraviolet radiation or certain drugs—alters expression of immune-related genes such as CD40LG and interferon pathway components (IFI44L), leading to heightened autoreactivity in T and B cells. These changes correlate with disease activity and organ involvement, positioning epigenetics as a bridge between environmental insults and lupus pathogenesis, with genome-wide studies confirming distinct methylation signatures in SLE patients versus healthy controls. Updates to the hygiene hypothesis further refine its role in autoimmunity, suggesting that excessive early-life antimicrobial exposure disrupts microbial colonization and skews immune development toward Th2/Th17 dominance. Some recent cohort studies suggest an association between antibiotic use in infancy and increased risk of autoimmune diseases, with adjusted hazard ratios ranging from 1.20 to 1.53 for conditions like type 1 diabetes and juvenile idiopathic arthritis, supporting a dose-response relationship. However, a large 2025 nationwide Korean cohort study of over 1 million children found no association between antibiotic exposure during pregnancy or early infancy and the overall incidence of autoimmune diseases, highlighting ongoing controversies in the field.^[180] A 2022 analysis of pediatric populations reinforced this debate, linking broad-spectrum antibiotics to elevated autoimmune onset in some subgroups, though conflicting nationwide data highlight the need for nuanced interpretations accounting for confounding factors like infection history. The altered glycan theory proposes that aberrant protein glycosylation generates neo-antigens that provoke autoimmune responses by mimicking danger signals. In this model, site-specific changes—such as hypogalactosylation of IgG at the CH2 domain—expose cryptic epitopes, enhancing interactions with Fc receptors and mannose-binding lectins to drive inflammation in diseases like rheumatoid arthritis. This theory predicts unique glycan signatures per autoimmune disorder, with preclinical evidence showing how environmental stressors induce these modifications, transforming self-glycans into immunogenic targets and amplifying autoantibody production.

Novel Therapeutic Approaches

Stem-cell therapies represent a promising frontier in autoimmune disease treatment, leveraging the immunomodulatory and regenerative properties of stem cells to reset aberrant immune responses and promote tissue repair. Mesenchymal stem cells (MSCs), derived from sources such as bone marrow or adipose tissue, have demonstrated potential in inducing remission in multiple sclerosis (MS) by suppressing pro-inflammatory T-cell activity and fostering remyelination in preclinical and early clinical studies. As of 2025, phase II trials, including those using autologous adipose-derived MSCs, have shown safety and efficacy in reducing neurofilament light chain levels—a marker of neuronal damage—and improving Expanded Disability Status Scale (EDSS) scores in relapsing-remitting MS patients, with ongoing efforts toward phase III evaluation to confirm long-term remission rates.^[181]^[182] In systemic sclerosis (scleroderma), autologous hematopoietic stem cell transplantation (HSCT) has achieved sustained remission by depleting autoreactive lymphocytes and allowing immune reconstitution, with long-term follow-up data indicating improved event-free survival and skin scores in patients with diffuse cutaneous disease compared to conventional therapies.^[183]^[184] Gene editing technologies, particularly CRISPR-Cas9, offer precise interventions to mitigate autoimmune triggers by targeting susceptibility genes. In preclinical models of type 1 diabetes (T1D), CRISPR-mediated editing of human leukocyte antigen (HLA) genes, such as knocking out HLA class I molecules (HLA-A, HLA-B, and β2-microglobulin) in beta cells or stem cell-derived progenitors, has generated immune-evasive insulin-producing cells that resist T-cell destruction without broad immunosuppression.^[185]^[186] These hypoimmunogenic cells, when transplanted into diabetic mouse models, restored normoglycemia and evaded allogeneic rejection, highlighting CRISPR's potential to address HLA-linked autoimmunity while preserving overall immune function.^[187] Antigen-specific immunotherapies aim to induce immune tolerance by presenting disease-relevant autoantigens in a controlled manner, reprogramming autoreactive T cells without global immune suppression. In rheumatoid arthritis (RA), phase I trials of tolerizing immunotherapies using citrullinated peptide liposomes combined with calcitriol have safely modulated anti-citrullinated protein antibody (ACPA)-positive responses, reducing pro-inflammatory cytokine production in synovial fluid and showing preliminary signs of clinical improvement in joint scores.^[188] Emerging antigen-specific approaches, such as those targeting collagen or vimentin peptides, are advancing toward phase II/III trials, with preclinical data indicating sustained tolerance and decreased disease progression in RA models.^[189]^[190] Vitamin D modulation addresses deficiencies common in autoimmune patients, which exacerbate immune dysregulation through impaired regulatory T-cell function and heightened Th17 activity. Randomized controlled trials (RCTs) from 2024 and 2025 have shown that high-dose supplementation (4,000 IU/day) in vitamin D-deficient individuals with RA reduces flare frequency and disease activity scores (DAS28) by enhancing anti-inflammatory pathways, with studies reporting reductions in tender joint counts after six months.^[191] Similar RCTs in other autoimmune conditions, such as systemic lupus erythematosus, confirm that correcting deficiency lowers autoantibody levels and flare rates, supporting targeted supplementation as an adjunctive strategy in at-risk populations.^[192]

Challenges in Autoimmunity Research

Autoimmune diseases exhibit significant heterogeneity, manifesting as variations in clinical presentation, disease severity, progression, and underlying pathogenic mechanisms even within the same diagnostic category. This variability complicates the design and interpretation of clinical trials, as patient cohorts may include subgroups with differing responses to interventions, leading to inconclusive results and challenges in establishing efficacy. For instance, in systemic lupus erythematosus (SLE), heterogeneous immune profiles hinder the identification of uniform therapeutic targets, often resulting in flawed trial endpoints that fail to capture disease-specific outcomes.^[193] The need for reliable biomarkers to stratify patients and predict treatment responses is thus a critical gap; current markers, such as autoantibody levels or cytokine profiles, often lack specificity due to this heterogeneity, impeding personalized medicine approaches. A major limitation in autoimmunity research stems from the poor translational validity of animal models, particularly mouse models, to human disease. These models, while useful for studying basic mechanisms like autoantibody production in lupus-prone strains, fail to recapitulate the complex genetic, environmental, and immunological heterogeneity observed in humans, leading to discrepancies in disease phenotypes and therapeutic outcomes. For example, therapies targeting pathways such as BAFF or IFN pathways show promise in mouse models of SLE but frequently underperform or fail in human trials due to differences in immune system architecture, including variations in toll-like receptor expression and complement activation. Overall, only about 5% of preclinical therapies tested in animal models achieve regulatory approval for human use, highlighting the low efficacy carryover and contributing to stalled progress in developing new treatments.^[194]^[195] Diagnostic delays represent another persistent challenge, with patients often experiencing prolonged periods from symptom onset to confirmed diagnosis, exacerbating disease progression and organ damage. Recent studies indicate an average delay of 3 to 5 years across various autoimmune conditions, such as SLE, where the median time from first symptoms to diagnosis is approximately 47 months, frequently involving multiple misdiagnoses and consultations with several providers. This lag is attributed to nonspecific early symptoms and the absence of sensitive diagnostic tools, resulting in irreversible complications like lupus nephritis upon eventual identification. Efforts to shorten these delays through improved screening protocols remain hampered by the lack of standardized, accessible testing.^[196] Equity issues further undermine autoimmunity research, as clinical trials often underrepresent diverse populations, including racial/ethnic minorities and women from low-socioeconomic backgrounds, limiting the generalizability of findings. Less than half of autoimmune trials report race/ethnicity data, and only a small fraction of NIH-funded projects prioritize women's health in this context, leading to knowledge gaps that perpetuate disparities in diagnosis and treatment efficacy. For instance, underrepresented groups face higher disease burdens yet receive therapies tested predominantly in homogeneous cohorts, potentially overlooking genetic or environmental factors that influence disease expression and response. Addressing this requires inclusive trial designs and increased funding for diverse recruitment to ensure equitable global applicability.^[197]

References

[1]
Autoimmune Diseases | NIAID
Mar 20, 2025 · In this family of disorders, the immune system mistakenly attacks healthy, working parts of the body, damaging them as a result. Researchers ...
[2]
Autoimmune Diseases | Autoimmune Disease Symptoms | MedlinePlus
### Summary of Autoimmune Diseases (MedlinePlus)
[3]
Autoimmune Diseases | National Institute of Environmental Health ...
But if the immune system malfunctions, it mistakenly attacks healthy cells, tissues, and organs. Called autoimmune disease, these attacks can affect any part of ...
[4]
Background on Autoimmune Diseases - NCBI - NIH
Autoimmune disease by definition, then, is autoimmunity that results over time in a pathological outcome with self-reactive, or autoreactive, T cells and ...
[5]
Autoimmune disorders: MedlinePlus Medical Encyclopedia
Jun 12, 2023 · An autoimmune disorder occurs when the body's immune system attacks and destroys healthy body tissue by mistake. There are more than 80 autoimmune disorders.Addison disease · Sjogren syndrome · Dermatomyositis · Myasthenia gravis
[6]
Autoimmune disease - The Lancet
Feb 4, 2006 · Possibly the first definition of autoimmune disease was provided by Paul Ehrlich in 1904 when he coined the term “horror autotoxicus”.
[7]
Origins and history of autoimmunity—A brief review
Sep 21, 2022 · Paul Ehrlich coined the term “horror autotoxicus” for autoimmunity and emphasized how the immune system distinguishes foreign from self. The ...Abstract · Key points · ORIGINS OF AUTOIMMUNITY · ADVANCEMENT AND...
[8]
Immune System and Disorders | Autoimmune Disease - MedlinePlus
Dec 26, 2023 · If you have an autoimmune disease, your immune system attacks healthy cells in your body by mistake. Other immune system problems happen when ...Missing: distinction | Show results with:distinction
[9]
Autoimmune responses are directed against self antigens - NCBI - NIH
Autoimmune disease occurs when a specific adaptive immune response is mounted against self antigens.<|separator|>
[10]
Challenges, Progress, and Prospects of Developing Therapies to ...
Apr 2, 2020 · ... autoimmune diseases. Indeed, autoimmune diseases affect approximately 5%–8% of the world population and cause tremendous suffering to ...
[11]
Classification of Autoimmune Diseases - Johns Hopkins Pathology
Organ-specific autoimmune diseases are those where a particular organ or tissue is preferentially targeted by the patient's immune system. For example, the ...
[12]
Overview of Select Autoimmune Diseases - NCBI - NIH
After Sjögren's disease, the chapter will provide information on three systemic autoimmune diseases—SLE, APS, and rheumatoid arthritis—followed by discussions ...
[13]
Biochemistry, Autoimmunity - StatPearls - NCBI Bookshelf - NIH
Dec 19, 2022 · Autoimmunity refers to an aberration in the body's normal development that causes the immune system to mount an attack against its cells.<|control11|><|separator|>
[14]
Untangling a Complex Web: How to Categorize Autoimmune Disease
In organ-specific autoimmune diseases, a person's immune system attacks a single system, organ, or tissue. Examples include Graves' disease in the thyroid gland ...
[15]
Undifferentiated Connective-Tissue Disease - Medscape Reference
Jul 1, 2025 · In 1980, LeRoy et al proposed the concept of undifferentiated connective-tissue syndromes (UCTS) to characterize mixed or overlapping syndromes.
[16]
Mixed connective tissue disease - Symptoms & causes - Mayo Clinic
Mixed connective tissue disease, also called MCTD, has symptoms of more than one rheumatic condition. These conditions include lupus, scleroderma and myositis. ...
[17]
Undifferentiated Connective Tissue Disease - Rheumatology Advisor
Aug 9, 2022 · UCTD refers to a condition presenting with symptoms and laboratory test results that suggest a systemic autoimmune disorder or connective tissue disease.
[18]
Mediators of central tolerance | Nature Reviews Immunology
Jun 25, 2015 · Thymic B cells directly present self-antigen for T cell negative selection.
[19]
Positional cloning of the APECED gene | Nature Genetics
Dec 1, 1997 · Nagamine, K. et al. Isolation of cDNA for a novel human protein ... Positional cloning of the APECED gene. Nat Genet 17, 393–398 (1997) ...
[20]
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells - Nature Immunology
### Summary: Key Role of FOXP3 in Treg Function
[21]
Mechanisms maintaining peripheral tolerance | Nature Immunology
Dec 17, 2009 · In this review, I discuss data that reveal barriers preventing peripheral T cell recognition of self-peptide–MHC complexes, as well as the physiological ...Abstract · Main · Author Information
[22]
https://www.nature.com/articles/ni904
[23]
Mechanisms of human autoimmunity - PMC - PubMed Central - NIH
The fundamental underlying mechanism of autoimmunity is defective elimination and/or control of self-reactive lymphocytes.
[24]
Autoimmune Diseases: Molecular Pathogenesis and Therapeutic ...
Jun 16, 2025 · Currently, autoimmune diseases lack a unified classification system but are commonly categorized based on the extent of tissue involvement into ...
[25]
Antigen presentation by B cells enables epitope spreading across ...
Oct 31, 2023 · Our findings demonstrate that B cells initiate and propagate the autoimmune response.
[26]
Evolving understanding of autoimmune mechanisms and new ...
Oct 4, 2024 · This review describes the common epidemiology, clinical manifestation and mechanisms of autoimmune diseases, with a focus on typical autoimmune diseases.
[27]
Th17 Cells in Inflammation and Autoimmunity - PubMed
T helper 17 (Th17), a distinct subset of CD4(+) T cells with IL-17 as their major cytokine, orchestrate the pathogenesis of inflammatory and autoimmune diseases ...
[28]
The regulation and differentiation of regulatory T cells and their ...
Feb 19, 2024 · We examine evidence for T reg cell dysfunction in the context of common autoimmune diseases such as multiple sclerosis, inflammatory bowel disease, systemic ...
[29]
Role of IL-17 in the Pathogenesis of Rheumatoid Arthritis - PMC
IL-17 (also known as IL-17A) is the signature cytokine of the newly-described “Th17” T helper cell population, and has been implicated in the pathogenesis ...
[30]
Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis - MDPI
This review covers existing knowledge regarding the roles of cytokines, related immune cells and the immune system in RA
[31]
Self-Antigen Presentation by Dendritic Cells in Autoimmunity - PMC
Feb 13, 2014 · The current review discusses the role of DCs in autoimmune diseases, the various factors involved in the induction and maintenance of tolerogenic DC phenotype.
[32]
The Role of Monocytes and Macrophages in Autoimmune Diseases
It has been quite well elucidated that Mo/Mϕ are key component of the innate immune system and are involved in both amplifying and suppressing inflammation (2).Abstract · Introduction · Mo and Mϕ in Autoimmune... · Conclusions and Future...
[33]
The interaction of innate immune and adaptive immune system - Wang
Sep 15, 2024 · The focus is on the crosstalk between the two immune systems and how they function together in diseases including infections, autoimmune ...INNATE IMMUNE SYSTEM · CROSSTALK BETWEEN... · DYSREGULATION OF...
[34]
The Genetics of Human Autoimmune Disease - PubMed Central - NIH
Missing Heritability. For most autoimmune diseases, estimates suggest that over 50% of the genetic loci contributing to heritability are not yet elucidated.
[35]
Twin concordance and sibling recurrence rates in multiple sclerosis
Probandwise concordance rates of 25.3% (SE ± 4.4) for monozygotic (MZ), 5.4% (±2.8) for dizygotic (DZ), and 2.9% (±0.6) for their nontwin siblings were found.
[36]
Common genetic factors among autoimmune diseases - Science
May 4, 2023 · Autoimmune diseases consistently demonstrate a higher concordance rate among monozygotic twins compared with dizygotic twins (35% and 6 ...
[37]
HLA Association with Autoimmune Diseases - NCBI - NIH
The HLA, as per almost all the ADs, has been shown to exert the strongest genetic association and effect on SLE to date. The top association was found at HLA- ...
[38]
Association of MHC and rheumatoid arthritis: HLA-DR4 and ... - NIH
Inherited susceptibility to rheumatoid arthritis (RA) is associated with the DRB1 genes encoding the human leukocyte antigen (HLA)-DR4 and HLA-DR1 molecules.
[39]
The HLA Region and Autoimmune Disease - PubMed Central - NIH
Strong association between the HLA region and autoimmune disease (AID) has been established for over fifty years. Association of components of the HLA class II ...
[40]
PTPN22: the archetypal non-HLA autoimmunity gene - PMC
PTPN22 is a major genetic risk factor for multiple connective tissue and other autoimmune diseases, including RA, JIA, PsA, SLE, SSc and some forms of ...
[41]
Autoimmunity-Related Risk Variants in PTPN22 and CTLA4 Are ...
Apr 8, 2020 · Both, the PTPN22 rs2476601 and CTLA4 rs3087243 SNPs were shown to be associated with numerous autoimmune diseases, including T1D, SLE, and RA (8 ...
[42]
Construction and Application of Polygenic Risk Scores in ... - NIH
Jun 27, 2022 · In this review, we describe the recent advances in GWAS for autoimmune diseases and the practical application of this knowledge to predict an ...
[43]
A catalog of GWAS fine-mapping efforts in autoimmune disease - NIH
Across all fine-mapping studies, we compiled 230 GWAS loci with allelic heterogeneity estimates and predictions of causal variants and trait-relevant genes.Causal Variants And The... · Figure 4 · Figure 5<|control11|><|separator|>
[44]
Identification of the shared genetic architecture underlying seven ...
Jan 7, 2024 · Genome wide association studies (GWAS) have discovered thousands of susceptibility loci related to ADs, and confirmed their polygenic property ( ...
[45]
Leaky Gut and Autoimmunity: An Intricate Balance in Individuals ...
Dec 21, 2020 · This review focuses on the relationship between the leaky gut and autoimmune diseases, causes of leaky gut, factors contributing to the healing of leaky gut.
[46]
Microbial dysbiosis in the gut drives systemic autoimmune diseases
Microbial dysbiosis is the main driver of local inflammatory and autoimmune diseases such as colitis and inflammatory bowel diseases.
[47]
All disease begins in the (leaky) gut: role of zonulin-mediated ... - NIH
Jan 31, 2020 · Celiac disease. Celiac disease (CD) is an autoimmune enteropathy triggered by the ingestion of gluten-containing grains in genetically ...The Zonulin Pathway And Its... · Role Of Zonulin Pathway In... · Autoimmune Disorders<|separator|>
[48]
Environmental Exposures, Epigenetic Changes and the Risk of Lupus
As noted above, environmental agents causing oxidative stress, including UV light, infections, and smoking, have been associated with risk of lupus or lupus ...
[49]
Drug-Induced Lupus Erythematosus - StatPearls - NCBI Bookshelf
Apr 3, 2023 · Drug-induced lupus (DIL) is an autoimmune phenomenon where a drug exposure leads to the development of systemic lupus erythematosus (SLE) ...Missing: toxins UV
[50]
Chronic Stress and Autoimmunity: The Role of HPA Axis and ...
Oct 14, 2025 · HPA axis dysregulation under chronic stress constitutes a critical mechanistic link between psychological stress and autoimmune disease.
[51]
Role of Sex Hormone Levels and Psychological Stress in the ...
Jun 5, 2017 · Autoimmune diseases in women are most likely due to changes in estrogen levels during mental, physical, pre-menopausal, post-menopausal, and ...
[52]
Vitamin D and Multiple Sclerosis: A Comprehensive Review - PMC
Higher levels of vitamin D are associated with reduced risk for developing multiple sclerosis (MS), and with reduced clinical activity in established MS.
[53]
Molecular Mimicry as a Mechanism of Autoimmune Disease - PMC
Molecular mimicry has typically been characterized on an antibody or T cell level. However, structural relatedness between pathogen and self does not account ...
[54]
Molecular Mimicry and Autoimmunity - PMC - PubMed Central - NIH
In conclusion, molecular mimicry has been linked to the pathogenesis of many autoimmune diseases. Here we review a few major examples of different autoimmune ...
[55]
The Enigmatic Role of Viruses in Multiple Sclerosis - PubMed Central
Feb 1, 2025 · In the case of MS, molecular mimicry between myelin basic protein (MBP) and the EBV latency antigen EBNA-1 is well documented, since CD8+ T cell ...<|control11|><|separator|>
[56]
Rheumatic Fever, Autoimmunity and Molecular Mimicry - NIH
Human monoclonal autoantibodies from acute rheumatic fever were produced from disease and reacted against cardiac myosin and the streptococcus and reacted with ...
[57]
the homologous domain in coxsackie B virus protein 2C and islet ...
Molecular mimicry in diabetes mellitus: the homologous domain in coxsackie B virus protein 2C and islet autoantigen GAD65 is highly conserved in the coxsackie B ...
[58]
Ganglioside Molecular Mimicry and Its Pathological Roles in Guillain ...
The pathogenesis is believed to involve molecular mimicry between epitopes on C. jejuni lipopolysaccharides and neural gangliosides, resulting in immunologic ...
[59]
Molecular Mimicry, Bystander Activation, or Viral Persistence
Several mechanisms often used to explain the association of autoimmunity and virus infection are molecular mimicry, bystander activation (with or without ...
[60]
Induction of experimental autoimmune encephalomyelitis in Lewis ...
Viral infections are thought to play an important role in the pathogenesis of multiple sclerosis potentially through molecular mimicry, but direct evidence ...
[61]
Why are women predisposed to autoimmune rheumatic diseases?
Size of the gender difference. Autoimmune diseases of all organ sites and systems affect approximately 8% of the population, around 78% of whom are women [1].
[62]
Why women have more autoimmune diseases than men - NIH
Many explanations have been proposed, including sex hormones, the X chromosome, microchimerism, environmental factors, and the microbiome. However, the ...
[63]
Estrogen up-regulates Bcl-2 and blocks tolerance induction of naïve ...
Furthermore, increased estrogen leads to up-regulation of Bcl-2, which is probably responsible for the enhanced survival of autoreactive B cells. Continued ...
[64]
Androgen-Induced Immunosuppression - PMC - PubMed Central
Androgen-mediated suppression of immune reactivity and inflammation increases the threshold for autoimmunity to develop, but likely lowers the threshold for ...
[65]
Hormones, pregnancy, and autoimmune diseases - PubMed - NIH
May 1, 1998 · SLE often flares during pregnancy, whereas RA commonly remits during pregnancy and flares or initially develops in the postpartum period.
[66]
The Impact of Menopause on Autoimmune and Rheumatic Diseases
The menopause may trigger the development of autoimmune rheumatic diseases; the most studied and described is RA, which is often diagnosed within a few years ...
[67]
The role of X-chromosome inactivation in female predisposition to ...
We propose that the phenomenon of X-chromosome inactivation in females may constitute a risk factor for loss of T-cell tolerance; specifically that skewed X- ...
[68]
High frequency of skewed X-chromosome inactivation in females ...
High frequency of skewed X-chromosome inactivation in females with autoimmune thyroid disease: a possible explanation for the female predisposition to thyroid ...<|control11|><|separator|>
[69]
Impact of early life ovariectomy on blood pressure and body ...
This is supported by evidence from experimental animal models of SLE showing that removal of estrogen in young female mice delays autoantibody production and ...
[70]
Fatigue in rheumatic diseases - PMC - PubMed Central
Fatigue is the most prevalent complaint in approximately 50–90% of patients with SLE, (63). In most cases, the cause of fatigue is unknown.
[71]
Fatigue and autoimmune disease - Harvard Health
Jan 16, 2024 · For many people with autoimmune disease, fatigue is the most debilitating symptom. Why autoimmune disease and fatigue go hand-in-hand is not ...
[72]
Cytokines and Fever: Mechanisms and Sites of Action - 1998
Feb 7, 2006 · The cytokines interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-α induce increases in body temperature via direct and indirect actions on the brain.<|control11|><|separator|>
[73]
The ying and yang of fever in rheumatic disease - PMC - NIH
Low grade fever is common in chronic inflammatory diseases. In both acute and chronic rheumatic diseases, the inflammatory process is driven by inflammatory ...
[74]
Cachexia (Wasting Syndrome): Symptoms & Treatment
Apr 15, 2024 · System-wide inflammation: Cancer and other chronic diseases cause inflammation that can lead to loss of fat and muscle. Insulin resistance: ...
[75]
What Are Common Symptoms of Autoimmune Disease?
Common Autoimmune Disease Symptoms · Fatigue · Joint pain and swelling · Skin problems · Abdominal pain or digestive issues · Recurring fever · Swollen glands.
[76]
Autoimmune Disorders of the Joints and Nerves - Everyday Health
Polymyalgia rheumatica, an inflammatory disorder, causes symptoms of muscle pain and stiffness, typically in the neck, shoulder, arms, or hip areas. Pain is ...Polymyalgia Rheumatica · Rheumatoid Arthritis · Beth Biggee, Md
[77]
Autoimmune Diseases: Signs, Symptoms, and Complications
Common signs of autoimmune disease include fatigue, skin rashes, stomach ache, swollen glands, recurring low-grade fever, joint aches, and muscle pain.
[78]
Autoimmune Diseases and Their Manifestations on Oral Cavity
Symptoms can vary from simple circular skin lesions to multiorgan impairment, potentially fatal. The most recurrent skin lesion is severe erythema on the ...
[79]
Preclinical Autoimmune Disease: a Comparison of Rheumatoid ...
In this narrative review we compare the preclinical disease course of four important autoimmune diseases with distinct phenotypes.
[80]
How Does Age at Onset Influence the Outcome of Autoimmune ... - NIH
The age at onset varies widely depending on the disease. For example, sixty-five percent of patients with systemic lupus erythematosus (SLE) start manifesting ...
[81]
Excitable dynamics of flares and relapses in autoimmune diseases
Nov 17, 2023 · One key factor is infections, which are known to often occur before flares in autoimmune diseases such as MS,50 lupus,4 and other diseases.
[82]
Outbursts in Autoimmunity: Disease Flare-ups
Common flare-up symptoms include depression, exhaustion, unusual rashes, poor sleep, fever, and increased pain. However, different autoimmune diseases feature ...Triggers, Body Responses... · Systemic Lupus Erythematosus... · Multiple Sclerosis (ms)...
[83]
Autoimmune Diseases: Types, Symptoms & Treatments
What are autoimmune disease symptoms? · A feeling of warmth or heat. · Discoloration or redness on your skin. · Swelling. · Pain.
[84]
Joint and muscle inflammatory disease: A scoping review of the ...
The spectrum of joint and muscle inflammatory diseases encompasses many diagnoses including primitive and secondary myositis associated with RA or arthritis ...Missing: musculoskeletal | Show results with:musculoskeletal
[85]
Idiopathic inflammatory myopathies – a guide to subtypes ...
The idiopathic inflammatory myopathies (IIMs) are a group of autoimmune conditions characterised by inflammation of muscle (myositis) and other organ systems.
[86]
Skin Manifestations Associated with Autoimmune Liver Diseases
In the present article, we provide a systematic literature review on skin manifestations linked to each of these four autoimmune liver diseases, excluding skin ...
[87]
Hair Disorders in Autoimmune Diseases - PMC - PubMed Central
Jan 24, 2023 · Alopecia in autoimmune disorders may manifest as patchy or diffuse alopecia, scarring or non-scarring alopecia, etc. [2].
[88]
Autoimmune Disorders of the Nervous System - Frontiers
Remarkable discoveries over the last two decades have elucidated the autoimmune basis of several, previously poorly understood, neurological disorders.
[89]
Patients with chronic autoimmune demyelinating polyneuropathies ...
Feb 4, 2020 · Patients with chronic autoimmune demyelinating polyneuropathies exhibit cognitive deficits which might be associated with CSF evidence of blood ...Missing: issues | Show results with:issues
[90]
Gastrointestinal Manifestations in Systemic Autoimmune Diseases
The presentation is usually systemic and includes fatigue, malaise, anorexia, fever, and weight loss. The disease predominantly affects women (F:M, 10:1) ...
[91]
A Diagnostic Approach to Autoimmune Disorders - Slack Journals
Jun 6, 2016 · In this article, we review the commonly performed laboratory tests used to diagnose autoimmune diseases. ... history and physical examination.
[92]
Autoimmune diseases - New insights into a troublesome field
In addition to the medical history, a basic physical examination and a special examination with equipment adapted to the clinical picture of the disease ...
[93]
Diagnostic Testing and Interpretation of Tests for Autoimmunity - NIH
This chapter discusses these components and includes a discussion about organ-specific immunologic diseases where immunological laboratory testing is employed.
[94]
The Blood in Rheumatology - NCBI - NIH
Jan 6, 2021 · The most common forms of hematologic manifestations in patients with SLE are anemia, leukopenia, thrombocytopenia, and the antiphospholipid ...Missing: CBC | Show results with:CBC
[95]
Hashimoto Thyroiditis - StatPearls - NCBI Bookshelf
Feb 9, 2025 · Thyroid antibodies: Thyroid peroxidase antibody is positive in over 90% of cases, whereas thyroglobulin antibody is positive in 50% to 80% of ...Etiology · History and Physical · Evaluation · Treatment / Management
[96]
Lupus & Kidney Disease (Lupus Nephritis) - NIDDK
Kidney disease caused by lupus may get worse over time and lead to kidney failure. If your kidneys fail, you will need dialysis or a kidney transplant.What is lupus nephritis? · What are the symptoms of... · What tests do health care...
[97]
Using MRI to Detect and Understand Autoimmune Disorders
Jul 17, 2023 · For example, in multiple sclerosis, MRI can detect brain and spinal cord lesions even before symptoms appear. In rheumatoid arthritis, it can ...
[98]
Whole-Body MRI in Rheumatology: Major Advances and Future ...
Whole-body magnetic resonance imaging is constantly gaining more importance in rheumatology, particularly for what concerns the diagnosis, follow-up, and ...
[99]
Sjögren disease | Radiology Reference Article - Radiopaedia.org
Sep 4, 2025 · Radiographic features. Ultrasound. Salivary glands. early stage: the gland can be normal or become enlarged and hyperechoic 5.
[100]
Advances in imaging techniques for Sjogren's disease - ScienceDirect
Sep 17, 2025 · New ultrasound techniques are currently being developed, including elastography for assessing tissue stiffness, analysis of microvascularization ...
[101]
Evaluation of Salivary Glands by Ultrasonography and Inflammatory ...
Aug 30, 2023 · Ultrasound ... Salivary gland involvement in autoimmune thyroiditis, with special reference to the degree of association with Sjögren's syndrome.
[102]
Skin Biopsy in the Context of Systemic Disease - ScienceDirect
This review focuses on some of the systemic processes with skin manifestations for which our basic understanding has changed most in recent decades.Review · Skin Biopsy In Diseases Of... · Skin Biopsy In Renal...
[103]
Kidney Biopsy and Immuno-Rheumatological Diseases
Jan 13, 2024 · Kidney biopsy remains fundamental to achieving the correct diagnosis and starting targeted therapy. Keywords: kidney biopsy, autoimmunity, ...
[104]
Muscle and Skin Biopsy - The Myositis Association
A muscle biopsy can diagnose myositis by distinguishing it from other muscle disorders. A doctor will remove muscle tissue to look for abnormalities.
[105]
Role of 18F-FDG PET/CT in Large Vessel Vasculitis and ...
Apr 1, 2023 · 18 F-FDG PET/CT plays an important role in the diagnostic work-up of GCA, PMR, and TAK and is increasingly used to monitor treatment response.
[106]
Role of 18F-FDG PET/CT in assessing systemic involvement in ...
Mar 20, 2025 · 18 F-FDG PET/CT has become a pivotal tool in diagnosing anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis.
[107]
Rheumatoid Arthritis Treatment Options
NSAIDs and corticosteroids have a short onset of action while DMARDs can take several weeks or months to demonstrate a clinical effect. DMARDs include ...
[108]
Systemic Lupus Erythematosus (SLE) Treatment & Management
Aug 21, 2024 · Hydroxychloroquine is recommended for all patients with SLE. Glucocorticoids can provide rapid symptom relief, but the medium- to long-term aim ...
[109]
https://www.myositis.org/about-myositis/diagnosis/muscle-skin-biopsy/
[110]
2021 American College of Rheumatology Guideline for the ... - NIH
Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild ...Missing: NSAIDs | Show results with:NSAIDs
[111]
https://pmc.ncbi.nlm.nih.gov/articles/PMC11925965/
[112]
Corticosteroid Adverse Effects - StatPearls - NCBI Bookshelf
Jul 3, 2023 · Glucocorticoids induced Osteoporosis is one of the well-known and devastating adverse effects of long-term use of glucocorticoids. Up to 40% of ...Indications · Administration · Adverse Effects · Monitoring
[113]
JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review ...
Sep 14, 2020 · During the FDA approval process, all 7 of tofacitinib's Phase III randomised control trials (RCTs) showed the efficacy of inhibiting JAK1/JAK3 ...
[114]
Review of an Anti-CD20 Monoclonal Antibody for the Treatment of ...
Jan 11, 2023 · One of the most studied B-cell-targeted therapies is rituximab, an anti-CD20 monoclonal antibody that exemplifies B-cell depletion therapy and ...
[115]
Efficacy of Anti-TNF Therapy for the Treatment of Patients with ... - NIH
The anti-TNF drugs are shown to be highly effective in treatment of patients with moderate-tosevere inflammatory bowel disease (IBD).
[116]
Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis
The net effect of tofacitinb's mechanism of action is decreased synovial inflammation and structural joint damage in RA patients. To date, six phase 3 trials ...
[117]
A 5-Year, 5130-Case Follow-Up from FIRST Registry - PMC - NIH
Apr 21, 2025 · Remission rates improved over time in the naïve group but remained largely unchanged in the prior b/tsDMARDs group. Retention rates varied by ...
[118]
Investigational CAR T Cell Gets Fast Tracked by U.S. FDA
The U.S. FDA granted Fast Track Designation for CABA-201, a CAR T cell investigational therapy from Cabaletta Bio for SLE and lupus nephritis.
[119]
Key considerations for advancing chimeric antigen receptor (CAR) T ...
Oct 5, 2025 · Early data have shown the efficacy of CAR T-cell therapy in refractory SLE, lupus nephritis (LN) and other autoimmune diseases that can be ...
[120]
Physical Therapy - Arthritis Foundation
A physical therapist can develop a movement plan to help keep you active. Physical therapy (PT) can help you get moving safely and effectively.
[121]
Joint Replacement Surgery - American College of Rheumatology
These surgeries involve removing worn cartilage from both sides of the joint, then resurfacing the joint with a metal and plastic implant.
[122]
Physiotherapy in Rheumatoid Arthritis - PMC - PubMed Central - NIH
Physiotherapy modalities are commonly used in the treatment of RA. These include cold/hot applications, electrical stimulation, and hydrotherapy.Missing: autoimmune | Show results with:autoimmune
[123]
Physiotherapy for Multiple Sclerosis Patients From Early to ...
Oct 27, 2022 · Kinesiotherapy, exercise rehabilitation, massage, and hydrotherapy are all forms of physiotherapy that are used as part of rehabilitation.
[124]
How Physical Therapy Can Help with Multiple Sclerosis
Nov 8, 2018 · Physical therapy, as part of a rehabilitation team that includes PT, occupational therapy and speech therapy, can help at every stage of MS.
[125]
Surgical Management of Graves' Disease
Thyroidectomy will be done under general anesthesia. An incision is made on the front of your neck to get to the thyroid gland. During the operation, the ...
[126]
Considerations for Thyroidectomy as Treatment for Graves Disease
Apr 24, 2019 · Recent evidence has shown that thyroidectomy is a very effective, safe treatment modality for hyperthyroidism and can be performed as an outpatient procedure.
[127]
Total Knee Arthroplasty Considerations in Rheumatoid Arthritis - PMC
The definitive treatment for advanced joint destruction in the late stages of rheumatoid arthritis can be successfully treated with total joint arthroplasty.
[128]
Lupus Nephritis - National Kidney Foundation
If your kidneys fail, you will need to have dialysis or a kidney transplant to survive. Up to 3 out of 10 people with lupus nephritis will develop kidney ...
[129]
Lupus nephritis - Diagnosis and treatment - Mayo Clinic
Jan 31, 2025 · Dialysis helps remove fluid and waste from the body, maintain the right balance of minerals in the blood, and manage blood pressure by filtering ...
[130]
Plasma Exchange (Plasmapheresis)
Plasma exchange helps by removing these abnormal antibodies from the blood. Plasma exchange involves removing a person's blood drawn and putting their blood ...
[131]
Therapeutic Plasma Exchange as a Treatment for Autoimmune ... - NIH
Jul 31, 2020 · Therapeutic plasma exchange (TPE) is commonly used as treatment of certain autoimmune neurological diseases (ANDs), and its main objective is the removal of ...
[132]
Palliative Care for Lupus
Jun 30, 2025 · In serious chronic illnesses such as lupus, palliative care aims to give a person with an illness the best possible quality of life.
[133]
Need for Palliative Care in Patient with Rheumatoid Arthritis - NIH
Palliative care physicians are mostly involved during the end-of-life care decisions in non-oncological chronic diseases. We studied the correlation of disease ...
[134]
Palliative Care in Rheumatology: Expanding the Scope
Aug 9, 2024 · Despite treatment advances, palliative care is underutilized in the rheumatology setting, especially when immunosuppressive therapies prove insufficient.
[135]
Mediterranean diet and rheumatoid arthritis: A nine-year cohort ...
May 7, 2025 · Higher adherence to MD was associated with a lower risk of RA. Our finding provides updated evidence on the importance of diet in RA development ...
[136]
A Brief Review of the Mediterranean Diet's Role in Mediating ...
Sep 22, 2025 · However, emerging clinical literature has shown its promise in reducing risk and disease activity in many autoimmune diseases.
[137]
How Future Pharmacologic Therapies for Celiac Disease Will ...
Apr 9, 2024 · The only proven treatment for celiac disease is adherence to a strict, lifelong, gluten-free diet. However, complete dietary gluten ...
[138]
Yoga for Systemic Lupus Erythematosus (SLE) - NIH
Yoga has shown improvements in quality-of-life and fatigue in various diagnoses. While there is growing evidence that yoga therapy may help osteoarthritis and ...
[139]
Yoga for systemic lupus erythematosus (SLE): Clinician experiences ...
Yoga has shown improvements in quality-of-life and fatigue in various diagnoses. While there is growing evidence that yoga therapy may help osteoarthritis and ...
[140]
A Review of the Efficacy of Influenza Vaccination in Autoimmune ...
May 13, 2021 · Overall, vaccination is generally well tolerated by SLE patients and the literature recommends the inactivated influenza vaccine to SLE patients.
[141]
Altered Immunocompetence | Vaccines & Immunizations - CDC
Jun 26, 2024 · Persons with altered immunocompetence generally are recommended to receive polysaccharide-based vaccines (PCV13, PPSV23, and Hib), on the basis of increased ...
[142]
UV exposure: What you need to know | Lupus Foundation of America
Jun 7, 2021 · Photosensitivity is common in people with lupus: 40% to 70% of people with lupus will find that their disease is made worse by exposure to UV ...
[143]
Screening for autoimmune diseases in apparently healthy ... - Frontiers
Aug 19, 2024 · Anti-nuclear antibodies (ANA) assessed by immunofluorescence (IF) microscopy are associated with systemic autoimmune rheumatic diseases (SARD)
[144]
Recommendations for Screening and Monitoring the Stages of Type ...
Jul 9, 2024 · Consequently, adults should be screened whenever an indication for testing or heightened risk is present, including family history of T1D and ...
[145]
Estimation of prevalence of autoimmune diseases in the United ...
This paper estimates the prevalence of all autoimmune disease in the US, sex- and age-adjusted, with individual estimates for 105 autoimmune diseases.
[146]
The Global Landscape of Autoimmune Disease
According to one study, autoimmune diseases cumulatively affect 5 to 10% of the industrial world population.
[147]
New study calculates autoimmune disease prevalence in U.S.
Jan 6, 2025 · The findings indicated that about 15 million people, or 4.6% of the U. S. population, were diagnosed with at least one autoimmune disease ...
[148]
Epidemiology of, risk factors for, and possible causes of rheumatoid ...
Sep 8, 2025 · The annual incidence of RA in the United States and northern European countries is estimated to be approximately 40 per 100,000 persons [2,4].
[149]
Multiple Sclerosis Epidemiology - Rare Disease Advisor
Jul 1, 2021 · Europe remains the region with the highest incidence, reaching 6.8 per 100,000 people, while the Americas register 4.8 and Southeast Asia ...
[150]
A Major Health Crisis: The Alarming Rise of Autoimmune Disease
Mar 28, 2024 · Autoimmune disease, a group of illnesses in which the immune system mistakenly attacks the body's own tissues, comprise more than 100 disorders ...Missing: International | Show results with:International
[151]
The Rise of Autoimmune Diseases | Sjögren's Foundation
Mar 26, 2025 · The incidence (rate of new cases) of global autoimmune diseases has risen yearly by 19.1% with rheumatological diseases such as Sjögren's and lupus rising 7.1% ...
[152]
Source of surging autoimmunity may lie in 'a thousand cuts' - Healio
Mar 25, 2024 · Although solid figures remain elusive, estimates place the number of Americans with autoimmune diseases at approximately 24 million. According ...Missing: EU | Show results with:EU
[153]
How Does Age at Onset Influence the Outcome of Autoimmune ...
Dec 13, 2011 · Rheumatoid arthritis (RA) can begin at any age but has its peak between ages 30 and 55 [5]. Juvenile idiopathic arthritis (JIA) is a term used ...
[154]
Autoimmune Disease in Women: Endocrine Transition and Risk ...
In the 20–50 year range, an early incidence peak of SLE has been reported in African American women but there were no significant differences in SLE incidence ...
[155]
Sex Differences in Autoimmune Disease from a Pathological ... - NIH
There is no significant difference in IL-17 (Th17 response) between males and females in three of four experiments, but IL-17 was significantly increased in ...
[156]
Systemic-onset juvenile idiopathic arthritis - ScienceDirect.com
SoJIA when considered as a JIA subtype includes about 10–20% of all JIA patients, but the percentage is higher in some countries and when only severe cases are ...
[157]
Systemic-onset juvenile idiopathic arthritis - Orphanet
Systemic-onset JIA accounts for roughly 10-20% of all JIA patients, with incidence estimated at 1/166,000 and prevalence at 1/32,000 in the prediatric ...
[158]
Lupus Facts and Statistics | Lupus Foundation of America
Apr 11, 2025 · Lupus is two to three times more prevalent among African American, Hispanic/Latina, Asian American, Native American, Alaska Native, Native Hawaiian and other ...
[159]
Gluten Intolerance by Country 2025 - World Population Review
The prevalence of celiac disease was 0.4% in South America, 0.5% in Africa and North America, 0.6% in Asia, and 0.8% in Europe and Oceania. The prevalence was ...
[160]
Racial Disparities in Celiac Disease Research, Testing, Diagnosis ...
Jun 7, 2021 · Over the years, celiac disease has been perceived as an autoimmune disorder mostly affecting Caucasians, particularly people of European descent.
[161]
Prevalence of autoimmune diseases is strongly associated with ...
Jul 10, 2025 · Vitamin D is essential for immune function, and its deficiency has been implicated in increased susceptibility to autoimmune disorders [3].
[162]
Does the environment influence multiple sclerosis pathogenesis via ...
Apr 15, 2019 · MS is characterized by a striking geographic variation of prevalence and incidence with a positive latitude gradient - the further away from ...
[163]
The latitude gradient for multiple sclerosis prevalence is established ...
Mar 11, 2021 · The latitude effect that we explore in this paper, whether that is vitamin D, sunlight, or some other environmental exposure that varies by ...
[164]
Autoimmune Health Crisis: An Inclusive Approach to Addressing ...
Oct 10, 2024 · For women, having a low income or being uninsured results in greater barriers to quality care, poorly treated or untreated chronic conditions, ...
[165]
The impact of social determinants of health on the presentation ... - NIH
Mar 29, 2023 · Worse SLE outcomes are associated with lower healthcare access, income, education and social support. Introduction. SLE is a multisystem ...Missing: barriers | Show results with:barriers
[166]
Neighborhood Deprivation and Risks of Autoimmune Disorders - NIH
Oct 9, 2019 · Our results indicate that neighborhood deprivation may affect risk of ADs, independent of individual level sociodemographic characteristics.Missing: barriers | Show results with:barriers
[167]
The Increasing Prevalence of Autoimmunity and ... - PubMed Central
Autoimmunity is defined by self-reactive components of the adaptive immune system, which cause clinically apparent pathology in the case of autoimmune diseases.
[168]
Autoimmunity Has Reached Epidemic Levels. We Need Urgent ...
Dec 1, 2023 · Most autoimmune diseases are being diagnosed in increasing numbers ranging from 3 to 12 percent annually across the globe. We also are finding ...
[169]
Incidence, prevalence, and co-occurrence of autoimmune disorders ...
Among these individuals, we identified 1 123 789 new diagnoses of autoimmune diseases, affecting a total of 978 872 individuals. The mean age when an autoimmune ...Missing: recognized | Show results with:recognized
[170]
Urban-associated diseases: Candidate diseases, environmental risk ...
This well-known environmental risk factor may explain urban associations of asthma, MS, CVD, cancer, mental health conditions and respiratory tract infections ( ...
[171]
The increasing prevalence of autoimmunity and ... - ScienceDirect.com
Evidence suggests that autoimmunity and autoimmune diseases are on the rise. •. Probable causes are changes in food, contacts with xenobiotics, air pollution, ...
[172]
Candidate diseases, environmental risk factors, and a path forward
Rates for allergic, inflammatory and auto-immune diseases appear to rise with urbanization and be higher in the more urbanized nations of the world which has ...
[173]
Results from the Global Burden of Disease Study 2021 - PubMed
Sep 10, 2025 · Projections suggest continued increases in age-standardized incidence and prevalence rates for most ADs through 2035.Missing: 2030 | Show results with:2030
[174]
Ageing and health - World Health Organization (WHO)
Oct 1, 2025 · By 2030, 1 in 6 people in the world will be aged 60 years or over. At this time the share of the population aged 60 years and over will increase ...UN Decade of Healthy Ageing · Decade of Healthy Ageing... · Ageism
[175]
Autoimmune Disease Prevalence Hits 5% in US: New Research
Feb 20, 2025 · The overall worldwide incidence of autoimmune diseases has risen by 19.1% annually. Specific conditions demonstrate varying growth rates.
[176]
Innovative center focuses on autoimmune disease prevention
Apr 16, 2025 · The Autoimmune Disease Prevention Center is launching a national trial to recruit those at risk for rheumatoid arthritis and focus on preventive treatments.
[177]
Mesenchymal stem cells in clinical trials for multiple sclerosis
Aug 22, 2025 · The findings suggest that MSC therapy holds potential for slowing disease progression and promoting neurological recovery in MS patients.
[178]
Adipose-Derived Mesenchymal Stem Cell Therapy Meets Primary ...
Sep 29, 2025 · A phase 2 study presented at ECTRIMS 2025 showed that autologous adipose-derived mesenchymal stem cell therapy was safe and effective in ...
[179]
Myeloablative Autologous Stem-Cell Transplantation for Severe ...
Jan 3, 2018 · Myeloablative autologous hematopoietic stem-cell transplantation achieved long-term benefits in patients with scleroderma, including improved event-free and ...
[180]
Long-term outcome of autologous haematopoietic stem cell ...
Oct 23, 2024 · AHSCT is more effective than both RTX and CIT in prolonging survival and inducing prolonged remission in patients with rapidly progressive dcSSc.
[181]
Immune-evasive beta cells in type 1 diabetes: innovations in genetic ...
In beta cell engineering, CRISPR is used to knock out genes (i.e., deleting HLA-A/B genes or β2M to remove HLA class I surface expression) or to knock in ...
[182]
[PDF] CRISPR-editing of hESCs allows for production of immune evasive ...
CRISPR-editing of hESCs allows for production of immune evasive cells capable of differentiation to pancreatic progenitors for future type 1.
[183]
Applications of Genome-Editing Technologies for Type 1 Diabetes
Dec 26, 2023 · In this review, we aim to provide an overview of the currently reported gene-editing models and interventions tested to prevent the onset of and treat T1D.
[184]
Randomized phase I trial of antigen-specific tolerizing ... - JCI Insight
Oct 24, 2022 · Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide/calcitriol liposomes in ACPA+ rheumatoid arthritis.
[185]
Review Toward immune tolerance in rheumatoid arthritis: Emerging ...
Sep 23, 2025 · This review explores novel immunotherapies, such as antigen-specific tolerizing immunotherapy (ASITI) and immune checkpoint agonism, designed to ...
[186]
Randomized phase I trial of antigen-specific tolerizing ... - PubMed
Oct 24, 2022 · Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide/calcitriol liposomes in ACPA+ rheumatoid arthritis. JCI ...
[187]
Impact of vitamin D supplementation on disease activity and pain ...
Jul 11, 2025 · Supplementation with 4000 IU/day of vitamin D can potentially improve disease activity and pain management among RA patients after six months.
[188]
High-dose Vitamin D supplementation for immune recalibration in ...
High-dose vitamin D can rebalance Th1/Th17 versus Treg activity, lessen disease flares, and boost standard therapies without raising serious safety concerns.
[189]
Challenges and Opportunities for Biomarkers of Clinical Response ...
Feb 2, 2018 · Heterogeneity within a given autoimmune disease can manifest as a spectra of disease severity, duration, clinical manifestations, and tissue ...
[190]
Mouse models of lupus: what they tell us and what they don't - PMC
Jan 21, 2018 · Efficacy and toxicity of compounds can vary significantly between humans and mice, also limiting direct translation. Finally, the heterogeneous ...
[191]
Analysis of animal-to-human translation shows that only 5% of ... - NIH
Jun 13, 2024 · ... animal models often failing in human studies [57]. On the other hand ... success rate of biomedical therapies' journey from animals to humans".
[192]
Understanding the impact of delayed diagnosis and misdiagnosis of ...
The median delay from the first symptom to diagnosis in SLE is 47 months, highlighting the need for early recognition and management. Delayed diagnosis can lead ...
[193]
Autoimmune Health Crisis: An Inclusive Approach to Addressing ...
Oct 10, 2024 · The gender gap in autoimmunity is undeniable and becomes particularly evident surrounding the three major hormonal transitions in a woman's life ...Missing: fluctuations | Show results with:fluctuations<|separator|>